What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2026-03-26 compared with 2025-03-31 · 1211 added, 1215 removed, 20 unchanged (99% of the section changed)

Risk factors that could cause actual results to

differ from our expectations and that could negatively impact our financial condition and results of operations are discussed below and

elsewhere in this Annual Report.

Additional risks and uncertainties not presently known to us or that are currently not believed

to be significant to our business may also affect our actual results and could harm our business, financial condition and results of operations.

any of the risks or uncertainties described below or any additional risks and uncertainties actually occur, our business, results of operations

and financial condition could be materially and adversely affected.

Risks Relating to Our Business

We have a limited operating history and we may never generate revenue

We are a clinical-stage biotechnology company that

commenced activities in January 2012.

We have a limited operating history, and our business plan has not been tested.

Since inception,

we have had no revenue and have incurred significant operating losses.

We have financed our operations primarily through equity and debt

To generate revenue and become and remain profitable, we need to successfully complete our existing clinical trials, cultivate

partnerships with pharmaceutical companies, and develop and commercialize gedatolisib pursuant to our license agreement with Pfizer.

must also build operational and financial infrastructure to support commercial operations, train and manage employees, and market and

sell our anticipated drug product.

We may never succeed in any of these activities and,

even if we do, we may never generate revenue that is sufficient to achieve profitability.

We expect to continue to incur significant expenses

and operating losses for the foreseeable future, and the net losses we incur may fluctuate significantly from quarter to quarter.

failure to become and remain profitable would decrease our value and could impair our ability to raise capital, maintain or expand our

research and development efforts, expand our business, or continue our operations.

Our inability to raise additional capital on acceptable terms in

the future may limit our ability to develop and commercialize our drug candidate, gedatolisib.

We will require additional capital to finance operating

expenses and capital expenditures over the next several years if we launch gedatolisib and expand our infrastructure, commercial operations

and research and development activities.

If we are not able to secure additional funding when needed, we may have to delay, reduce the

scope of or eliminate one or more research and development programs or selling and marketing initiatives.

In addition, we may have to

work with a partner on one or more of our products or market development programs, which could lower the economic value of those programs

to our company.

Future financing activities could dilute the percentage ownership

of our stockholders and could cause our stock price to fall or could result in operating or other restrictions.

We may seek to raise additional capital through equity

offerings, debt financings, collaborations or licensing arrangements.

Additional funding may not be available to us on acceptable terms,

If we raise funds by issuing equity securities, it will result in dilution to current stockholders.

Any equity securities issued

may also provide for rights, preferences or privileges senior to those of holders of our existing securities.

The incurrence of additional

indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also include restrictive

covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire

or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business.

In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms.

We are dependent on our ability to attract and retain key personnel.

Our operations are materially dependent upon the services

of our officers and key employees, including Brian F.

Sullivan, our Chief Executive Officer, and Dr.

Laing, our Chief Science

Successful implementation of our business plan will also require the services of other consultants and additional personnel.

We cannot assure you that we will be able to attract and retain such persons as employees, independent contractors, consultants or otherwise.

If we are not able to attract individuals with the skills required for our business, or if we lose the services of either Mr.

factors that could cause actual results to differ from our expectations and that could negatively impact our financial condition and

results of operations are discussed below and elsewhere in this Annual Report.

Additional risks and uncertainties not presently known

to us or that are currently not believed to be significant to our business may also affect our actual results and could harm our business,

financial condition and results of operations.

If any of the risks or uncertainties described below or any additional risks and uncertainties

actually occur, our business, results of operations and financial condition could be materially and adversely affected.

Relating to Our Business

have not yet commercialized a pharmaceutical product, and we may never generate revenue or profit.

are a clinical-stage biotechnology company that commenced activities in January 2012.

We have not yet commercialized a

pharmaceutical product, and our commercial business plan has not been tested.

Since inception, we have had no revenue and have

incurred significant operating losses.

We have financed our operations primarily through private placements and registered offerings

of our equity securities, unsecured convertible notes, and borrowings under loan agreements.

To generate revenue and become and

remain profitable, we need to successfully complete our existing clinical trials and develop, obtain regulatory approval for, and

commercialize gedatolisib pursuant to our license agreement with Pfizer.

We must also build operational and financial infrastructure

to support commercial operations, train and manage employees, and market and sell our anticipated drug product, if

may never succeed in any of these activities and, even if we do, we may never generate revenue that is sufficient to achieve profitability.

We expect to continue to incur significant expenses and operating losses for the foreseeable future, and the net losses we incur may

fluctuate significantly from quarter to quarter.

Our failure to become and remain profitable would decrease our value and could impair

our ability to raise capital, maintain or expand our research and development efforts, expand our business, or continue our operations.

inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize our drug candidate,

may require additional capital to finance operating expenses and capital expenditures in the future as we prepare to launch, and if we

launch, gedatolisib, and expand our infrastructure, commercial operations and research and development activities.

If we are not able

to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development

programs or selling and marketing initiatives.

In addition, we may have to work with a partner on one or more of our products or market

development programs, which could lower the economic value of those programs to our company.

financing activities could dilute the percentage ownership of our stockholders and could cause our stock price to fall or could result

in operating or other restrictions.

may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements.

funding may not be available to us on acceptable terms, or at all.

If we raise funds by issuing equity securities, it will result in

dilution to current stockholders.

Any equity securities issued may also provide for rights, preferences or privileges senior to those

of holders of our existing securities.

The incurrence of additional indebtedness or the issuance of certain equity securities could result

in increased fixed payment obligations and could also include restrictive covenants, such as limitations on our ability to incur additional

debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions

that could adversely affect our ability to conduct our business.

In the event that we enter into collaborations or licensing arrangements

to raise capital, we may be required to accept unfavorable terms.

are dependent on our ability to attract and retain key personnel.

operations are materially dependent upon the services of our officers and key employees, including Brian F.

Sullivan, our Chief Executive

Officer, and Dr.

Laing, our Chief Science Officer.

Successful implementation of our business plan will also require the services

of other consultants and additional personnel.

We cannot assure you that we will be able to attract and retain such persons as employees,

independent contractors, consultants or otherwise.

If we are not able to attract individuals with the skills required for our business,

or if we lose the services of either Mr.

Sullivan or Dr.

Laing, we may be unable to successfully implement our business plan.

Product liability claims may damage our reputation and, if insurance

proves inadequate, these claims may harm our business.

We may be exposed to the risk of product liability

claims that is inherent in the biopharmaceutical industry.

A product liability claim may damage our reputation by raising questions about

our product’s safety and efficacy and could limit our ability to sell one or more products by preventing or interfering with commercialization

of our drug candidate.

In addition, product liability insurance for the biopharmaceutical industry is generally expensive to the extent

it is available at all.

There can be no assurance that we will be able to obtain or maintain such insurance on acceptable terms for any

product we bring to market.

Further, our product liability insurance coverage may not provide coverage or may be insufficient to reimburse

us for any or all expenses or losses we may suffer.

A successful claim against us with respect to uninsured liabilities or in excess of

insurance coverage could have a material adverse effect on our business, financial condition and results of operations.

We expect to expand our development and regulatory capabilities and

potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth,

which could disrupt our operations.

We expect to experience significant growth in the

number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and, if our

product candidate receives marketing approval, sales, marketing and distribution.

To manage our anticipated future growth, we must continue

to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional

qualified personnel.

Due to our limited financial and human resources, we may not be able to effectively manage the expansion of our operations

or recruit and train additional qualified personnel.

The expansion of our operations may lead to significant costs and may divert our

management and business development resources.

Any inability to manage growth could delay the execution of our business plans or disrupt

our operations.

Risks Related to Our Product Strategy

Our near-term revenue prospects depend on the success of our initial

drug product, gedatolisib.

If we are unable to successfully complete clinical development of, obtain regulatory approval for or commercialize

gedatolisib, or if we experience delays in doing so, our business will be materially harmed.

To date, we have not yet completed any registrational

clinical trials or the development of our initial drug candidate, gedatolisib.

Our future success and ability to generate revenue, which

we do not expect until 2026 or later, if ever, is dependent on our ability to successfully develop, obtain regulatory approval for and

commercialize gedatolisib for one or more intended uses.

We may not have the financial resources to continue development of, or to modify

existing or enter into new collaborations for, our current or future product candidates if we experience any issues that delay or prevent

regulatory approval of, or our ability to commercialize, gedatolisib, including:

● our inability to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that gedatolisib is safe

and effective;

● insufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;

● negative or inconclusive results from our clinical trials or the clinical trials of others for drug products similar to ours, leading

to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program;

● product-related adverse events experienced by subjects in our clinical trials or by individuals using drugs or therapeutic biologics

similar to gedatolisib;

● delays in submitting applications, delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial,

or a suspension or termination of a clinical trial once commenced;

● conditions imposed by the FDA or comparable foreign regulatory authorities regarding the scope or design of our clinical trials;

● poor effectiveness of gedatolisib or companion therapeutics during clinical trials;

● better than expected performance of control arms, such as placebo groups, which could lead to negative or inconclusive results from

our clinical trials;

● delays in enrolling subjects in clinical trials;

● high drop-out rates of subjects from clinical trials;

● inadequate supply or quality of drug products or other materials necessary for the conduct of our clinical trials;

● greater than anticipated clinical trial or manufacturing costs;

● unfavorable FDA or comparable regulatory authority inspection and review of a clinical trial site;

● failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual

obligations in a timely manner, or at all;

● delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight

around clinical testing generally or with respect to our therapies in particular;

● varying interpretations of data by the FDA and comparable foreign regulatory authorities.

We were not involved in the early development of gedatolisib;

we are dependent on third parties having accurately generated, collected, interpreted and reported data from certain preclinical and clinical

trials of gedatolisib.

We had no involvement with or control over the initial

preclinical and clinical development of gedatolisib.

We are dependent on third parties having conducted their research and development

in accordance with the applicable protocols and legal, regulatory and scientific standards;

having accurately reported the results of

all preclinical studies and clinical trials conducted with respect to such drug product;

and having correctly collected and interpreted

the data from these trials.

If these activities were not compliant, accurate or correct, the clinical development, regulatory approval

or commercialization of our drug product will be delayed and may be adversely affected.

We have not yet successfully completed any registrational clinical

trials, and we may be unable to do so for any drug candidates we may develop.

We will need to successfully complete registrational

clinical trials in order to obtain the approval of the FDA or comparable foreign regulatory authorities to market our drug product.

out clinical trials, including later-stage registrational clinical trials, is a complicated process.

As an organization, we have not previously

completed any registrational clinical trials.

In order to do so, we are building and expanding our clinical development and regulatory

capabilities, and there is risk that we may be unable to recruit and train qualified personnel.

We also expect to continue to rely on

third parties to conduct our clinical trials.

If these third parties do not successfully carry out their contractual duties, meet expected

deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any product candidates.

Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to submission

and approval of our drug product.

liability claims may damage our reputation and, if insurance proves inadequate, these claims may harm our business.

may be exposed to the risk of product liability claims that is inherent in the pharmaceutical industry.

A product liability claim may

damage our reputation by raising questions about our product’s safety and could limit our ability to sell our product.

product liability insurance for the pharmaceutical industry is generally expensive to the extent it is available at all.

no assurance that we will be able to obtain or maintain such insurance on acceptable terms for any product we bring to market.

our product liability insurance coverage may not provide coverage or may be insufficient to reimburse us for any or all expenses or losses

we may suffer.

A successful claim against us with respect to uninsured liabilities or in excess of insurance coverage could have a material

adverse effect on our business, financial condition and results of operations.

are expanding our development and regulatory capabilities and implementing sales, marketing and distribution capabilities, and as a result,

we may encounter difficulties in managing our growth, which could disrupt our operations.

are experiencing significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug

development, regulatory affairs and, in anticipation of our product candidate potentially receiving marketing approval, sales, marketing

and distribution.

To manage this growth, we must continue to implement and improve our managerial, operational and financial systems,

and continue to recruit and train additional qualified personnel.

Due to finite financial and human resources, we may not be able to

effectively manage the expansion of our operations or recruit and train sufficient numbers of additional qualified personnel.

The expansion

of our operations is costly and may divert our management and business development resources.

Any inability to manage growth could delay

the execution of our business plans or disrupt our operations.

to trade policy, including new or increased tariffs and changing import and export regulations, could have a material adverse effect

on our business, results of operations and financial condition.

business, results of operations, and financial condition could be adversely affected by uncertainty and changes in U.S.

or international

trade policies, including tariffs, quotas, trade agreements, or other trade restrictions imposed by the U.S.

or other governments.

example, the U.S.

has instituted certain changes, and has proposed additional changes, in trade policies that include the negotiation

or termination of trade agreements, the imposition of higher tariffs on imports into the U.S., and other government regulations affecting

trade between the U.S.

and other countries.

New tariffs and other changes in U.S.

trade policy have triggered, and may in the future

trigger, retaliatory actions by affected countries, and foreign governments may institute or may consider imposing trade sanctions on

Several recent tariff announcements have been followed by announcements of limited exemptions, revisions, and temporary pauses,

resulting in significant uncertainty.

increasing uncertainty related to trade policies, on February 20, 2026, the U.S.

Supreme Court ruled against the U.S.

administration’s use of tariffs under the International Emergency Economic Powers Act (the “IEEPA”).

decision creates uncertainty related to various aspects of the tariffs previously collected under the IEEPA, and not all tariffs

announced throughout 2025 were impacted by this U.S.

Supreme Court decision.

Additionally, in response to the U.S.

Supreme Court

ruling, the U.S.

presidential administration imposed a new worldwide tariff effective for 150 days from February 24, 2026.

imposition of these new, worldwide tariffs, as well as the potential for further tariff actions by the U.S.

administration or others, represents a significant source of uncertainty.

The imposition of tariffs and other trade restrictions, as

well as the escalation of trade disputes and any downturns in the global economy resulting therefrom, could materially and adversely

affect our business, financial condition and results of operations.

The extent and duration of the tariffs and other trade

restrictions and the resulting impact on general economic conditions and on our business are uncertain and depend on various

factors, such as negotiations between the U.S.

and affected countries, the responses of other countries or regions, exemptions or

exclusions that may be granted, and availability and cost of alternative sources of supply.

imposition of, or increase in, tariffs or other restrictions on imports of active pharmaceutical ingredient (“API”), finished

drug product or other materials (or the components of these materials) could increase the cost for such API, finished drug product or

other materials and also increase the prices for such materials available domestically or locally, if any, which in turn could increase

our costs for API and our finished drug product.

Such cost increases could materially and adversely affect our results of operations

and financial condition.

Tariffs or other trade restrictions may lead to continuing uncertainty and volatility in U.S.

and global financial

and economic conditions and commodity markets, declining consumer confidence, significant inflation, and diminished expectations for

Such conditions could have a material adverse impact on our business, results of operations and financial position.

indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our

business, financial condition and results of operations and impair our ability to satisfy our debt obligations.

of December 31, 2025, we had $338.8 million aggregate principal amount of indebtedness for borrowed money, of which $130.0 million was

secured indebtedness consisting of the Term Loans (as defined in Note 10 to our financial statements included elsewhere in this Annual

Included in the aggregate principal amount is $201.3 million principal amount of additional indebtedness as a result of the

offering of the Company’s 2.750% Senior Notes due 2031 (the “Notes”).

We may incur additional indebtedness to meet

future financing needs.

For example, we have an additional $220.0 million in incremental Term Loans that can be drawn under the A&R

Loan Agreement (as defined in Note 10 to our financial statements included elsewhere in this Annual Report) upon the achievement of certain

regulatory milestones and product revenue thresholds.

Our indebtedness could have significant negative consequences for our security

holders and our business, results of operations and financial condition by, among other things:

our vulnerability to adverse economic and industry conditions;

our ability to obtain additional financing on acceptable terms or at all;

the dedication of a substantial portion of our cash flow from operations to service our indebtedness,

which will reduce the amount of cash available for other purposes;

our flexibility to plan for, or react to, changes in our business;

the interests of our existing stockholders as a result of issuing shares of our common stock

upon conversion of the Notes;

us at a possible competitive disadvantage with competitors that are less leveraged than us

or have better access to capital.

business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under

our indebtedness, and our cash needs may increase in the future.

In addition, the A&R Loan Agreement contains, and any future indebtedness

that we may incur in the future may contain, financial and other restrictive covenants that limit our ability to operate our business,

raise capital or make payments under our other indebtedness.

If we fail to comply with these covenants or to make payments under our

indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness

becoming immediately due and payable in full.

may be unable to raise the funds necessary to repurchase the Notes for cash following a fundamental change or to pay any cash amounts

due upon maturity, and our other indebtedness may limit our ability to repurchase the Notes or to pay any cash amounts due upon their

may, subject to a limited exception, require us to repurchase their Notes following a fundamental change at a cash repurchase price generally

equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental

change repurchase date.

Upon maturity of the Notes, we must pay their principal amount and accrued and unpaid interest in cash, unless

they have been previously converted, redeemed or repurchased.

We may not have enough available cash or be able to obtain financing at

the time we are required to repurchase the Notes or pay any cash amounts due upon their maturity.

In addition, applicable law, regulatory

authorities and the agreements governing our other indebtedness may restrict our ability to repurchase the Notes or to pay any cash amounts

due upon their maturity.

Our failure to repurchase Notes or to pay any cash amounts due upon their maturity when required will constitute

a default under the indenture, dated as of August 1, 2025, between the Company and U.S.

Bank Trust Company, National Association, as

trustee (the “Base Indenture”), as supplemented by the first supplemental indenture (the “Supplemental Indenture,”

and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”).

A default under the Indenture or

the fundamental change itself could also lead to a default under agreements governing our other indebtedness, which may result in that

other indebtedness becoming immediately payable in full after any applicable notice or grace periods.

We may not have sufficient funds

to satisfy all amounts due under our indebtedness.

in the Indenture could delay or prevent an otherwise beneficial takeover of us.

provisions in the Notes and the Indenture could make a third-party attempt to acquire us more difficult or expensive.

For example, if

a takeover constitutes a fundamental change, then, subject to limited exceptions, Noteholders will have the right to require us to repurchase

their Notes for cash.

In addition, if a takeover constitutes a make-whole fundamental change, then we may be required to temporarily

increase the conversion rate of the Notes.

In either case, and in other cases, our obligations under the Notes and the Indenture could

increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing incumbent management, including

in a transaction that holders of our common stock may view as favorable.

Related to Our Product Strategy

near-term revenue prospects depend on the success of our initial drug product, gedatolisib.

If we are unable to successfully complete

clinical development of, obtain regulatory approval for, or commercialize, gedatolisib, or if we experience delays in doing so, including

supply chain interruptions, our business will be materially and adversely impacted.

future success and ability to generate revenue, if ever, is dependent on our ability to successfully develop, obtain regulatory approval

for and commercialize gedatolisib for one or more intended uses.

We may not have the financial resources to continue development of,

or to modify existing or enter into new collaborations for, our current or future product candidates if we experience any issues that

delay or prevent regulatory approval of, or our ability to commercialize, gedatolisib, including:

inability to demonstrate to the satisfaction of the FDA or comparable foreign regulatory

authorities that gedatolisib is safe and effective;

or inconclusive results from our clinical trials or the clinical trials of others for drug

products similar to ours, leading to a decision or requirement to conduct additional preclinical

studies or clinical trials or abandon a program;

● product-related

adverse events experienced by subjects in our clinical trials or by individuals using drugs

or therapies similar to gedatolisib;

effectiveness of gedatolisib or companion therapeutics during clinical trials;

than expected performance of control arms, such as placebo groups, which could lead to negative

or inconclusive results from our clinical trials;

drop-out rates of subjects from clinical trials;

supply or quality of drug products or other materials necessary for the conduct of our clinical

trials or to support commercialization;

than anticipated clinical trial or manufacturing costs;

● unfavorable

FDA or comparable regulatory authority inspection and review of a clinical trial site;

of our third-party contractors or investigators to comply with regulatory requirements or

otherwise meet their contractual obligations in a timely manner, or at all;

and changes in regulatory requirements, policy and guidelines, including the imposition of

additional regulatory oversight around clinical testing generally or with respect to our

therapies in particular;

● interruptions

to our supply of API, finished drug product or other materials;

interpretations of our clinical data by the FDA and comparable foreign regulatory authorities.

were not involved in the early development of gedatolisib;

therefore, we are dependent on third parties having accurately generated,

collected, interpreted and reported data from certain preclinical and clinical trials of gedatolisib.

had no involvement with or control over the initial preclinical and clinical development of gedatolisib.

We are dependent on third parties

having conducted their research and development in accordance with the applicable protocols and legal, regulatory and scientific standards;

having accurately reported the results of all preclinical studies and clinical trials conducted with respect to such drug product;

having correctly collected and interpreted the data from these trials.

have not yet successfully completed any registrational clinical trials, and we may be unable to do so for any drug candidates we may

will need to successfully achieve primary clinical endpoints in registrational clinical trials, in order to obtain and maintain the approval

of the FDA or comparable foreign regulatory authorities to market our drug product.

Carrying out clinical trials, including later-stage

registrational clinical trials, is a complicated process.

As an organization, we have not previously completed any registrational clinical

In order to do so, we continue to build and expand our clinical development and regulatory capabilities, and there is risk that

we may be unable to recruit and train qualified personnel.

We also expect to continue to rely on third parties to conduct our clinical

If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory

requirements, we may not be able to obtain regulatory approval of or commercialize any product candidates.

Consequently, we may be unable

to successfully and efficiently execute and complete necessary clinical trials in a way that leads to submission, approval, and maintaining

approval of our drug product.

We may require more time and incur greater costs than our competitors and may not succeed in obtaining

2 unchanged sentences

could prevent us from or delay us in commercializing our drug products.

The successful development of our products is highly uncertain.

Our business depends on the successful development

of biopharmaceuticals, which is highly uncertain and is dependent on numerous factors, many of which are beyond our control.

Product candidates

that appear promising in the early phases of development may fail to reach the market for several reasons including, among other things,

that clinical trial results may show the product candidates to be less effective than expected or to have unacceptable side effects or

we may fail to receive the necessary regulatory approvals or there may be a delay in receiving such approvals;

or the proprietary

rights of others and their competing products and technologies may prevent our product candidates from being commercialized.

The length of time necessary to complete clinical

trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly from one

drug product to the next and from one country to the next and may be difficult to predict.

We will incur significant research and development

expenses before knowing whether our products are commercially viable, and may abandon development of a specific trial, or a product candidate,

at any time for a variety of reasons.

If we expend resources on products that are ultimately not commercially viable, our timing for becoming

profitable and our ability to invest in other products in our pipeline would be adversely affected.

In addition, if gedatolisib

receives marketing approval for the intended uses that we are pursuing, we will continue to be subject to significant post-approval regulatory

Compliance with these requirements is costly, and any failure to comply or other issues with our drug products post-approval

could adversely affect our business, financial condition and results of operations.

In addition, there is always the risk that we, a regulatory

authority or a third party might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated

severity or frequency.

If we encounter difficulties enrolling patients in any of our clinical

trials, our clinical development activities could be delayed or otherwise adversely affected.

The timely completion of clinical trials in accordance

with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until

its conclusion.

We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:

● the patient eligibility and exclusion criteria defined in the protocol;

● the size of the patient population required for analysis of the clinical trial’s primary endpoints;

● the proximity of patients to clinical trial sites;

● the design of the clinical trial;

● our ability to recruit clinical trial investigators with the appropriate competencies and experience, and the ability of these investigators

to identify and enroll suitable patients;

● perception of the safety profile of our drug products;

● our ability to obtain and maintain patient consents;

● the risk that patients enrolled in clinical trials will drop out of the trials before completion.

Delays in patient enrollment may result in increased

costs or may affect the timing or outcome of our clinical trials, which could prevent completion of these trials and adversely affect

our ability to advance the development of our product candidates.

Interim, topline and preliminary data from our clinical studies that

we announce or publish from time to time may change as more data becomes available and are subject to audit and verification procedures

that could result in material changes in the final data.

From time to time, we may publicly disclose preliminary

or topline data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related

findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study.

make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity

to fully and carefully evaluate all data.

As a result, the topline results that we report may differ from future results of the same studies,

or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated.

data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary

data we previously published.

As a result, topline data should be viewed with caution until the final data are available.

time, we may also disclose interim data from our clinical studies.

Interim data from clinical studies that we may complete are subject

to the risk that one or more of the clinical outcomes may materially change as more patient data becomes available.

Adverse differences

between preliminary or interim data and final data could significantly harm our reputation and marketing efforts.

Further, others, including healthcare providers or

payors, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance

of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular

product candidate or product and our company in general.

In addition, the information we choose to publicly disclose regarding a particular

study is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise

appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant

with respect to future decisions, conclusions, views, activities or otherwise regarding our business.

If the topline or interim data that

we report differ from actual results, or if others, including healthcare providers or payors, disagree with the conclusions reached, our

ability to commercialize our product candidate may be harmed, which could harm our business, operating results, prospects or financial

Clinical development involves a lengthy and expensive process, with

an uncertain outcome.

We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development

and commercialization of our product candidates.

To obtain the requisite regulatory approvals to commercialize

any drug products, we must demonstrate through extensive preclinical studies and clinical trials that such drug product is safe and effective

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain.

We may be unable

to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can

fail at any stage of testing.

Differences in trial design between early-stage clinical

trials and later-stage clinical trials, which involve a greater number of patients and take years to complete, make it difficult to extrapolate

the results of earlier clinical trials to later clinical trials.

Moreover, clinical data are often susceptible to varying interpretations

and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless

failed to obtain marketing approval of their products.

Additionally, we are conducting and plan to conduct some open-label clinical trials,

where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing

approved drug or placebo.

Most typically, open-label clinical trials test only the investigational product candidate and sometimes may

do so at different dose levels.

Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect

as patients in those trials are aware when they are receiving treatment.

Open-label clinical trials may be subject to a “patient

bias” where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment.

In addition, open-label clinical trials may be subject to an “investigator bias” where those assessing and reviewing the outcomes

of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more

favorably given this knowledge.

Where a randomized, placebo-controlled clinical trial is designed to allow enrolled subjects to cross-over

to the treatment arm, there may be a risk of inadvertent unblinding of subjects prior to cross-over, which may limit the clinical meaningfulness

of those data and may require the conduct of additional clinical trials.

As such, the results from an open-label clinical trial may not

be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when

studied in a controlled environment with a placebo or active control.

Successful completion of clinical trials is a prerequisite

to submitting a new drug application, or NDA, to the FDA and similar marketing applications to comparable foreign regulatory authorities

for each drug product and, consequently, the ultimate approval and commercial marketing of any drug products.

We may experience delays

in initiating or completing clinical trials, including if it takes longer than expected to activate the targeted number of clinical sites,

if the enrollment of patients is slower than anticipated or negatively affected by staffing shortages at clinical sites, or by other unanticipated

factors, or if the FDA or other regulatory authorities require us to pause one or more of our clinical trials due to unexpected safety

We also may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct

that could delay or prevent our ability to receive marketing approval or commercialize our current product candidates or any future product

Our costs will increase if we experience delays in

clinical testing or marketing approvals.

We do not know whether our clinical trials will begin or continue as planned, will need to be

reassigned or will be completed on schedule, or at all.

Significant clinical trial delays also could shorten any periods during which

we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before

we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of

Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly.

We face significant competition, and our operating results will suffer

if we fail to compete effectively.

Our industry is characterized by intense competition

and rapid innovation.

Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results

than our lead product candidate, gedatolisib.

Our potential competitors include major multinational pharmaceutical companies, established

biotechnology companies, specialty pharmaceutical and diagnostic companies, and universities and other research institutions.

our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and

experienced marketing and manufacturing organizations and well-established sales forces.

Smaller or early-stage companies may also prove to

be significant competitors, particularly as they develop novel approaches to treating disease indications that gedatolisib is also focused

Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics

or to in-license novel therapeutics that could make the product candidates that we develop obsolete.

Mergers and acquisitions in the biotechnology

and pharmaceutical industries may result in even more resources being concentrated in our competitors.

Competition may increase further as a result of advances

in the commercial applicability of technologies and greater availability of capital for investment in these industries.

Our competitors,

either alone or with collaboration partners, may succeed in developing, acquiring or licensing on an exclusive basis products that are

more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or

secure patent protection that we may need for the development of our technologies and products.

We believe the key competitive factors

that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience

of use, price, and reimbursement.

Even if we obtain regulatory approval of drug products,

the availability and price of our competitors’ products could limit the demand and the price we are able to charge for our product

We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition

or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other

new drug or biologic products or choose to reserve our product candidates for use in limited circumstances.

If our information technology systems or data, or those of third

parties upon which we rely, are or were compromised, we could face clinical trial delays;

successful development of our products is highly uncertain.

business depends on the successful development of our pharmaceutical products, which is highly uncertain and is dependent on numerous

factors, many of which are beyond our control.

Product candidates that appear promising in the early phases of development may fail to

reach the market for several reasons including, among other things, that clinical trial results may show the product candidates to be

less effective than expected or to have unacceptable side effects or toxicities;

we may fail to receive the necessary regulatory approvals

or there may be a delay in receiving such approvals;

or the proprietary rights of others and their competing products and technologies

may prevent our product candidates from being commercialized.

length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory

authority varies significantly from one drug product to the next and from one country to the next and may be difficult to predict.

will incur significant research and development expenses before knowing whether our products are commercially viable, and may abandon

development of a specific trial, or a product candidate, at any time for a variety of reasons.

If we expend resources on products that

are ultimately not commercially viable, our timing for becoming profitable and our ability to invest in other products in our pipeline

would be adversely affected.

addition, if gedatolisib receives marketing approval for the intended uses that we are pursuing,

we will continue to be subject to significant post-approval regulatory obligations.

Compliance with these requirements is costly, and

any failure to comply or other issues with our drug products post-approval could adversely affect our business, financial condition and

results of operations.

In addition, there is always the risk that we, a regulatory authority, or a third party might identify previously

unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency.

we encounter difficulties enrolling patients in any of our clinical trials, our clinical development activities could be delayed or otherwise

adversely affected.

timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient

number of patients who remain in the trial until its conclusion.

We may experience difficulties in patient enrollment in our clinical

trials for a variety of reasons, including:

patient eligibility and exclusion criteria defined in the protocol;

size of the patient population required for analysis of the clinical trial’s primary

proximity of patients to clinical trial sites;

design of the clinical trial;

ability to recruit clinical trial investigators with the appropriate competencies and experience,

and the ability of these investigators to identify and enroll suitable patients;

of the safety profile of our drug products;

ability to obtain and maintain patient consents;

risk that patients enrolled in clinical trials will drop out of the trials before completion.

in patient enrollment may result in increased costs or may affect the timing or outcome of our clinical trials, which could prevent completion

of these trials and adversely affect our ability to advance the development of our product candidates.

topline and preliminary data from our clinical studies that we announce or publish from time to time may change as more data become available

and are subject to audit and verification procedures that could result in material changes in the final data.

time to time, we may publicly disclose preliminary or interim data from our clinical studies, which is based on a preliminary analysis

of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review

of the data related to the particular study.

We also make assumptions, estimations, calculations and conclusions as part of our analyses

of data, and we may not have received or had the opportunity to fully and carefully evaluate all data.

As a result, the preliminary or

interim results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify

such results once additional data have been received and fully evaluated.

Preliminary or interim data also remain subject to audit and

verification procedures that may result in the final data being materially different from the preliminary data we previously published.

As a result, preliminary or interim data should be viewed with caution until the final data are available.

Adverse differences between

preliminary or interim data and final data could significantly harm our reputation and marketing efforts.

others, including healthcare providers or payors, may not accept or agree with our assumptions, estimates, calculations, conclusions

or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the

approvability or commercialization of the particular product candidate or product and our company in general.

In addition, the information

we choose to publicly disclose regarding a particular study is based on what is typically extensive information, you or others may not

agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we

determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise

regarding our business.

If the preliminary or interim data that we report differ from actual results, or if others, including healthcare

providers or payors, disagree with the conclusions reached, our ability to commercialize our product candidate may be harmed, which could

harm our business, operating results, prospects or financial condition.

development involves a lengthy and expensive process, with an uncertain outcome.

We may incur additional costs or experience delays in

completing, or ultimately be unable to complete, the development and commercialization of our product candidates.

obtain the requisite regulatory approvals to commercialize any drug product, we must demonstrate through extensive preclinical studies

and clinical trials that such drug product is safe and effective in humans.

Clinical testing is expensive and can take many years to

complete, and its outcome is inherently uncertain.

We may be unable to establish clinical endpoints that applicable regulatory authorities

would consider clinically meaningful, and a clinical trial can fail at any stage of testing.

in trial design between early-stage clinical trials and later-stage clinical trials, which involve a greater number of patients and take

years to complete, make it difficult to extrapolate the results of earlier clinical trials to later clinical trials.

Moreover, clinical

data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed

satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products.

Additionally, we are conducting

and plan to conduct some open-label clinical trials, where both the patient and investigator know whether the patient is receiving the

investigational product candidate or either an existing approved drug or placebo.

Most typically, open-label clinical trials test only

the investigational product candidate and sometimes may do so at different dose levels.

Open-label clinical trials are subject to various

limitations that may exaggerate any therapeutic effect as patients in those trials are aware when they are receiving treatment.

clinical trials may be subject to a “patient bias” where patients perceive their symptoms to have improved merely due to

their awareness of receiving an experimental treatment.

In addition, open-label clinical trials may be subject to an “investigator

bias” where those assessing and reviewing the outcomes of the clinical trials are aware of which patients have received treatment

and may interpret the information of the treated group more favorably given this knowledge.

Where a randomized, placebo-controlled clinical

trial is designed to allow enrolled subjects to cross-over to the treatment arm, there may be a risk of inadvertent unblinding of subjects

prior to cross-over, which may limit the clinical meaningfulness of those data and may require the conduct of additional clinical trials.

As such, the results from an open-label clinical trial may not be predictive of future clinical trial results with any of our product

candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.

completion of clinical trials, or achievement of a predefined primary endpoint, is a prerequisite to submitting an NDA, or NDA supplement,

to the FDA, and similar marketing applications to comparable foreign regulatory authorities, for each drug product and, consequently,

the ultimate approval and commercial marketing of any drug products.

We may experience delays in initiating or completing clinical trials,

or achieving event thresholds, including if it takes longer than expected to activate the targeted number of clinical sites, if the enrollment

of patients is slower than anticipated or negatively affected by staffing shortages at clinical sites, or by other unanticipated factors,

or if the FDA or other regulatory authorities require us to pause one or more of our clinical trials due to unexpected safety issues.

We also may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct that could

delay or prevent our ability to receive marketing approval or commercialize our current product candidates or any future product candidates.

costs will increase if we experience delays in clinical testing or marketing approvals.

We do not know whether our clinical trials will

begin or continue as planned, will need to be reassigned or will be completed on schedule, or at all.

Significant clinical trial delays

also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our

competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates

and harming our business and results of operations.

Any delays in our clinical development programs may harm our business, financial

condition and results of operations significantly.

face significant competition, and our operating results will suffer if we fail to compete effectively.

industry is characterized by intense competition and rapid innovation.

Our competitors may be able to develop other compounds or drugs

that are able to achieve similar or better results than our lead product candidate, gedatolisib.

Our potential competitors include major

multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, and universities and

other research institutions.

Many of our competitors have substantially greater financial, technical and other resources, such as larger

research and development staff and experienced marketing and manufacturing organizations and well-established sales forces.

or early-stage companies may also prove to be significant competitors, particularly as they develop novel approaches to treating disease

indications that gedatolisib is also focused on treating.

Established pharmaceutical companies may also invest heavily to accelerate

discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop

Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated

in our competitors.

may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for

investment in these industries.

Our competitors, either alone or with collaboration partners, may succeed in developing, acquiring or

licensing on an exclusive basis products that are more effective, safer, more easily commercialized or less costly than our product candidates

or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products.

We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy,

safety, tolerability, reliability, convenience of use, price, and reimbursement.

if we obtain regulatory approval of drug products, the availability and price of our competitors’ products could limit the demand

and the price we are able to charge for our product candidates.

We may not be able to implement our business plan if the acceptance of

our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment

to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates

for use in limited circumstances.

our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could face clinical

trial delays;

regulatory investigations or actions;

1 unchanged sentence

disruptions of our business operations;

reputational harm;

and other adverse consequences.

Cyberattacks, malicious internet-based activity, online

and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information

and information technology systems, and those of the third parties upon which we rely.

We rely on contract research organizations, contract

manufacturing organizations, distributors, supply chain resources, and other third-party service providers and technologies to operate

critical business systems to process sensitive information in a variety of contexts, including, without limitation, on-site systems and

cloud-based data centers, systems handling human resources, financial reporting and controls, customer relationship management, regulatory

compliance, and other infrastructure operations.

We also communicate sensitive data, including patient data, electronically, and through

relationships with multiple third-party vendors and their subcontractors.

These applications and data encompass a wide variety of sensitive

information, including research and development information, patient data, commercial information, and business and financial information.

Our ability to monitor these third parties’ security practices is limited, and these third parties may not have adequate security

measures in place.

If we or any of our third-party service providers experience a security incident or other interruption, we could experience

adverse consequences.

We cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners’

supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption

to our information technology systems or the third-party information technology systems that support us and our services.

Cybersecurity threats are becoming increasingly difficult

to detect, and come from a variety of sources, including without limitation, nation-state actors and activists that create disruption

for geopolitical reasons and in conjunction with military conflicts and defense activities.

This risk is heightened during times of war

and other major conflicts, including the war between Russia and Ukraine, the conflict between Israel and Hamas and the risk of a larger

regional conflict.

In addition, we and the third parties upon which we rely face an evolving cybersecurity threat landscape, which includes

social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks),

malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service

attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software

bugs, server malfunctions, attacks enhanced or facilitated by artificial intelligence (“AI”), software or hardware failures,

loss of data or other information technology assets, adware, telecommunications failures, natural disasters, terrorism, and other similar

The majority of our employees and contractors work

Remote work involves risks to our information technology systems and data, as individuals utilize network connections, computers

and devices outside our premises or network, including working at home, while in transit and in public locations.

Ransomware attacks also continue to increase in prevalence

and severity and can lead to significant interruptions in our operations, ability to provide our services, loss of data and income, reputational

harm, and diversion of funds.

Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or

unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.

While we take steps designed to identify, prevent,

assess and mitigate vulnerabilities in our information systems and to mitigate related third-party risks, there can be no assurance that

we will be able to detect and remediate all such vulnerabilities, including on a timely basis.

The threats and techniques used to exploit

vulnerabilities change frequently and are often sophisticated in nature.

Therefore, we (or third parties on whom we rely) may be unable

to detect a vulnerability until after a security incident has occurred.

Further, we or third parties on which we rely may face downtime

as a result of adopting new information technology systems that are designed to enhance compliance or reduce vulnerabilities.

A security incident or other interruption could result

in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access

to our sensitive information or our information technology systems, or those of the third parties upon whom we rely.

This could disrupt

our clinical trials, damage our reputation, and negatively affect our ability to conduct our business in the ordinary course, including

our ability to collect, process, and prepare company financial information, provide information and educational materials through our

website, and manage the administrative aspects of our business.

We may expend significant resources or modify our

business activities (including our clinical trial activities) to try to protect against security incidents.

Additionally, certain data

privacy and security obligations may require us to implement and maintain certain measures to protect our information technology systems

and sensitive information and to notify relevant stakeholders, including affected individuals, regulatory authorities and our stockholders,

of certain security incidents.

The disclosure decisions are complex, may take time to determine, and may be subject to change as an investigation

Providing disclosure may be costly, and the failure to comply with such requirements could also lead to adverse consequences.

If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we

may face government enforcement actions (for example, investigations, fines, penalties, audits, and inspections);

additional reporting

requirements and/or oversight;

restrictions on processing sensitive information (including personal information);

litigation (including

class claims) and mass arbitration;

Cyberattacks,

malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and

availability of our sensitive information and information technology systems, and those of the third parties upon which we rely.

on contract research organizations, contract manufacturing organizations, distributors, supply chain resources, and other third-party

service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including,

without limitation, on-site systems and cloud-based data centers, systems handling human resources, financial reporting and controls,

customer relationship management, regulatory compliance, and other infrastructure operations.

We also communicate sensitive data, including

patient data, electronically, and through relationships with multiple third-party vendors and their subcontractors.

These applications

and data encompass a wide variety of sensitive information, including research and development information, patient data, commercial

information, and business and financial information.

Our ability to monitor these third parties’ security practices is limited,

and these third parties may not have adequate security measures in place.

If we or any of our third-party service providers experience

a security incident or other interruption, we could experience adverse consequences.

We cannot guarantee that third parties and infrastructure

in our supply chain or our third-party partners’ supply chains have not been compromised or that they do not contain exploitable

defects or bugs that could result in a breach of or disruption to our information technology systems or the third-party information technology

systems that support us and our services.

Cybersecurity

threats are becoming increasingly difficult to detect, and come from a variety of sources, including without limitation, nation-state

actors and activists that create disruption for geopolitical reasons and in conjunction with military conflicts and defense activities.

This risk is heightened as a result of global wars and other major conflicts.

In addition, we and the third parties upon which we rely

face an evolving cybersecurity threat landscape, which includes social-engineering attacks (including through deep fakes, which may be

increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including

as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel

misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, attacks enhanced or facilitated by

artificial intelligence (“AI”), software or hardware failures, loss of data or other information technology assets, adware,

telecommunications failures, natural disasters, terrorism, and other similar threats.

majority of our employees and contractors work remotely.

Remote work involves risks to our information technology systems and data, as

individuals utilize network connections, computers and devices outside our premises or network, including working at home, while in transit

and in public locations.

attacks also continue to increase in prevalence and severity and can lead to significant interruptions in our operations, ability to

provide our services, loss of data and income, reputational harm, and diversion of funds.

Extortion payments may alleviate the negative

impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations

prohibiting such payments.

we take steps designed to identify, prevent, assess and mitigate vulnerabilities in our information systems and to mitigate related third-party

risks, there can be no assurance that we will be able to detect and remediate all such vulnerabilities, including on a timely basis.

The threats and techniques used to exploit vulnerabilities change frequently and are often sophisticated in nature.

Therefore, we (or

third parties on whom we rely) may be unable to detect a vulnerability until after a security incident has occurred.

Further, we or third

parties on which we rely may face downtime as a result of adopting new information technology systems that are designed to enhance compliance

or reduce vulnerabilities.

security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction,

loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of

the third parties upon whom we rely.

This could disrupt our clinical trials, damage our reputation, and negatively affect our ability

to conduct our business in the ordinary course, including our ability to collect, process, and prepare company financial information,

provide information and educational materials through our website, and manage the administrative aspects of our business.

may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against

security incidents.

Additionally, certain data privacy and security obligations may require us to implement and maintain certain measures

to protect our information technology systems and sensitive information and to notify relevant stakeholders, including affected individuals,

regulatory authorities and our stockholders, of certain security incidents.

The disclosure decisions are complex, may take time to determine,

and may be subject to change as an investigation progresses.

Providing disclosure may be costly, and the failure to comply with such

requirements could also lead to adverse consequences.

If we (or a third party upon whom we rely) experience a security incident or are

perceived to have experienced a security incident, we may face government enforcement actions (for example, investigations, fines, penalties,

audits, and inspections);

additional reporting requirements and/or oversight;

restrictions on processing sensitive information (including

personal information);

litigation (including class claims) and mass arbitration;

indemnification obligations;

negative publicity;

reputational harm;

monetary fund diversions;

interruptions

in our operations (including availability of data);

interruptions in our operations (including availability of data);

financial loss;

and other similar harms.

Accordingly, security incidents and attendant

consequences may damage our financial position and negatively impact our ability to grow and operate our business.

Further, if the information technology systems of

the third parties upon which we rely become subject to security incidents, we may have insufficient recourse against such third parties,

and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent

future events of this nature from occurring.

There can be no assurance that limitations of liability in our third-party contracts are

sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.

We cannot be sure

that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our data privacy

and security practices.

Additionally, we cannot be sure that such coverage will continue to be available on commercially reasonable terms

or at all, or that such coverage will pay future claims.

In addition to experiencing a security incident, third

parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively

sensitive details about our organization and could be used to undermine our competitive advantage or market position.

Additionally, our

sensitive information could be leaked, disclosed, or revealed as a result of or in connection with our employees’, personnel’s,

or vendors’ use of generative AI technologies.

Public health matters may materially and

adversely impact our business, including ongoing clinical trials.

The outbreak of COVID-19

and government measures taken in response demonstrated that public health matters have a significant impact on the global economy, with

healthcare systems particularly affected.

Future outbreaks or variants of COVID-19, or the emergence of other pandemics or public health

disruptions, could materially and adversely impact our clinical trials, business, financial condition and results of operations.

disruptions include but are not limited to:

● delays or difficulties in enrolling patients in clinical trials and obtaining the results of completed clinical trials;

● increased rates of patients withdrawing from clinical trials following enrollment as a result of quarantine or public health concerns;

● diversion of healthcare resources away from the conduct of clinical trials;

● delays in prospective clinical trial collaborations with pharmaceutical companies and sponsors;

● interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;

● limitations on our ability to recruit and hire key personnel due to our inability to meet with candidates because of travel restrictions;

● limitations on employee resources that would otherwise be focused on the conduct of clinical trials and research as a result of focus

on health matters and loss of productivity from remote work.

Artificial intelligence presents risks and challenges that can impact

our business including by posing security risks to our confidential information, proprietary information and personal data.

Issues in the use of artificial intelligence, combined

with an uncertain regulatory environment, may result in reputational harm, liability or other adverse consequences to our business operations.

As with many technological innovations, artificial intelligence presents risks and challenges that could impact our business.

may incorporate generative artificial intelligence tools into their offerings without disclosing this use to us, and the providers of

these generative artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards with respect

to privacy and data protection and may inhibit our or our vendors’ ability to maintain an adequate level of service and experience.

If any of our vendors experiences an actual or perceived breach or privacy or security incident because of the use of generative artificial

intelligence, we may lose valuable intellectual property and confidential information and our reputation and the public perception of

the effectiveness of our security measures could be harmed.

Further, bad actors around the world use increasingly sophisticated methods,

including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information,

confidential information and intellectual property.

Any of these outcomes could damage our reputation, result in the loss of valuable

property and information, and adversely impact our business.

Risks Related to Product Development and Product Regulation

If we are unable to obtain approval from the FDA or comparable foreign

regulatory authorities to market our products for their intended use, we will not be able to generate revenue.

For a new drug to be approved

for marketing, the FDA and other regulatory authorities must determine that the drug is safe and effective.

Because all drugs can have

adverse effects, the data from our Phase 3 clinical study must demonstrate to the satisfaction of the FDA and other health authorities

that the benefits of gedatolisib in combination with palbociclib and fulvestrant, gedatolisib in combination with fulvestrant, or gedatolisib

in combination with fulvestrant plus a CDK4/6 inhibitor, outweigh its risks.

Failure to demonstrate sufficient magnitude of benefit, even

if the benefit is found to be statistically significant, may not support regulatory approval.

The marketability of our products, particularly gedatolisib,

depends on securing approval from the FDA and equivalent foreign regulatory bodies.

This requires rigorous pre-clinical and clinical studies,

including Phase 3 clinical trials for each intended use, that the benefits of the therapy outweigh its risks.

Failure to demonstrate sufficient

magnitude of benefit, even if the benefit is found to be statistically significant, may not support regulatory approval.

of the FDA’s regulatory requirements typically takes many years and requires substantial resources for research, development and

a drug meets its primary efficacy endpoint objective in a Phase 3 clinical trial, and the drug sponsor has additional nonclinical

and clinical data required by the FDA or other regulatory authorities, the drug sponsor may submit an NDA seeking marketing

Upon submission of an NDA, these health authorities perform a benefit-risk assessment that considers the strength and

quality of evidence available and takes remaining uncertainties into account.

These considerations include an assessment of the

strengths and limitations of clinical trials, including design, and potential implications for assessing drug efficacy, the

magnitude of benefit and interpretation of clinical importance, the benefit attributed to the drug when studied in combination with

other therapies, and the clinical relevance of the study endpoints.

We are currently conducting a Phase 3 clinical trial,

VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib, in patients with HR+/HER2-

advanced breast cancer after progression on CDK4/6 therapy , conducting a Phase 3

clinical trial, VIKTORIA-2, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment

for patients with endocrine treatment resistant HR+/HER2- advanced breast cancer, and

conducting a Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with

metastatic castration resistant prostate cancer.

We have sought

feedback from the FDA and other regulatory authorities on the design of gedatolisib clinical trials, with the goal of addressing these

considerations in the clinical trials’ design.

However, due to the complexity of clinical trials, the uncertainty of outcomes, and

the uncertainty of how the FDA and other regulatory authorities may balance benefits and risks in their review of an NDA, it may not be

practical or possible to address all benefit-risk assessment considerations in a clinical trial so that sufficient evidence is generated

to support a marketing approval, even if the primary endpoint objective is achieved in the Phase 3 stage of the trial.

The FDA or other

regulatory authorities may require us to redesign or conduct additional unplanned clinical trials before granting any approval and we

may not get approval at all.

Regulatory approval may also be delayed by changes in government regulation, future legislation or

administrative action or changes in FDA policy that occur prior to or during our regulatory review.

We cannot predict whether our research

and clinical approaches will result in a drug that the FDA considers safe for humans and effective for indicated uses.

In light of these

uncertainties, t he results from clinical trials that we conduct may not support approval of gedatolisib.

If regulatory

approvals are delayed or not obtained, especially with respect to gedatolisib, it will negatively impact our ability to commercialize

our products and generate revenue and may diminish any competitive advantages that we may otherwise enjoy .

If we are required to conduct additional clinical trials or other testing of gedatolisib beyond those that we currently contemplate, if

we are unable to successfully complete clinical trials or other testing of gedatolisib, or if the results of these trials or tests are

not positive or are only modestly positive or if there are safety concerns, we may:

● be delayed in obtaining marketing approval or not obtain marketing approval at all;

● obtain approval for indications or patient populations that are not as broad as intended or desired;

● obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;

● be subject to changes in the way our products are administered;

● be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;

● have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the

form of the FDA’s Risk Evaluation and Mitigation Strategies program (“REMS”) or through modification to an existing

● experience damage to our reputation.

Additionally, if the size of the FDA group dedicated

to reviewing oncology-related submissions is reduced, further delays of any regulatory submission by Celcuity may be encountered.

Breakthrough Therapy Designation or Fast Track Designation from the

FDA may not actually lead to a faster development or regulatory review or approval process.

If a drug is intended for the treatment of a serious

or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the product

sponsor may apply for Fast Track Designation.

The designation offers the opportunity for frequent interactions with the FDA to discuss

the drug’s development plan and to ensure collection of appropriate data needed to support drug approval, as well as eligibility

for submission of a New Drug Application.

In addition, a drug may receive Breakthrough Therapy

Designation if it is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease

or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies

on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.

of Breakthrough Therapy Designation include more intensive guidance from the FDA on an efficient development program, access to a scientific

liaison to help accelerate review time, and potential eligibility for priority review if relevant criteria are met.

This designation can

expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening

Both Fast Track and Breakthrough Therapy Designations

are within the discretion of the FDA.

While the FDA has granted both designations to our lead drug candidate, gedatolisib, such designations

may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA

procedures, and neither designation assures ultimate approval by the FDA.

In addition, the FDA may later decide that the product no longer

meets the qualification conditions and may rescind either or both such designations.

Obtaining and maintaining regulatory approval of our product candidates

in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.

Obtaining and maintaining regulatory approval of our

product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other

jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory

approval process in others.

For example, even if the FDA grants marketing approval of a product candidate, a comparable foreign regulatory

authority must also approve the manufacturing, marketing and promotion of the product candidate in those countries.

Approval procedures vary among jurisdictions and can

involve requirements and administrative review periods different from, and greater than, those in the U.S., including additional preclinical

studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions.

In many jurisdictions outside the U.S., a product candidate must be approved for reimbursement before it can be approved for sale in that

jurisdiction.

In some cases, the price that we intend to charge for our products is also subject to approval.

Obtaining foreign regulatory approvals and compliance

with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the

introduction of our products in certain countries.

If we fail to comply with the regulatory requirements in international markets and/or

receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our

product candidates will be harmed.

Even if we receive initial regulatory approvals, we will be subject

to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject

to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.

If any of our product candidates are approved, they

will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling,

record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-marketing information, including both

federal and state requirements in the U.S.

and requirements of comparable foreign regulatory authorities.

In addition, we will be subject

to continued compliance with requirements for any clinical trials that we conduct post-approval.

Manufacturers and manufacturers’ facilities

are required to comply with extensive FDA and comparable foreign regulatory authority requirements.

Accordingly, we and others with whom

we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and

quality control.

Any regulatory approvals that we receive for our product

candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of

approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to

monitor the safety and efficacy of the product candidate.

Certain endpoint data we hope to include in any approved product labeling also

may not make it into such labeling, including exploratory or secondary endpoint data such as patient-reported outcome measures.

may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems

occur after the product reaches the market.

Later discovery of previously unknown problems with our product candidates, including adverse

events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply

with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-marketing

studies or clinical trials to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program.

Accordingly, security incidents and attendant consequences may damage our financial position and negatively impact our ability to grow

and operate our business.

if the information technology systems of the third parties upon which we rely become subject to security incidents, we may have insufficient

recourse against such third parties, and we may have to expend significant resources to mitigate the impact of such an event, and to

develop and implement protections to prevent future events of this nature from occurring.

There can be no assurance that limitations

of liability in our third-party contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy

and security obligations.

We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate

liabilities arising out of our data privacy and security practices.

Additionally, we cannot be sure that such coverage will continue

to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.

addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public

sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine

our competitive advantage or market position.

Additionally, our sensitive information could be leaked, disclosed, or revealed as a result

of or in connection with our employees’, personnel’s, or vendors’ use of generative AI technologies.

intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information,

proprietary information and personal data.

in the use of artificial intelligence, combined with an uncertain regulatory environment, may result in reputational harm, liability

or other adverse consequences to our business operations.

As with many technological innovations, artificial intelligence presents risks

and challenges that could impact our business.

Our vendors may incorporate generative artificial intelligence tools into their offerings

without disclosing this use to us, and the providers of these generative artificial intelligence tools may not meet existing or rapidly

evolving regulatory or industry standards with respect to privacy and data protection and may inhibit our or our vendors’ ability

to maintain an adequate level of service and experience.

If any of our vendors experiences an actual or perceived breach or privacy or

security incident because of the use of generative artificial intelligence, we may lose valuable intellectual property and confidential

information and our reputation and the public perception of the effectiveness of our security measures could be harmed.

actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities

involving the theft and misuse of personal information, confidential information and intellectual property.

Any of these outcomes could

damage our reputation, result in the loss of valuable property and information, and adversely impact our business.

health matters may materially and adversely impact our business, including ongoing clinical trials.

outbreak of COVID-19 and government measures taken in response demonstrated that public health matters have a significant impact on the

global economy, with healthcare systems particularly affected.

Future outbreaks or variants of COVID-19, or the emergence of other pandemics

or public health disruptions, could materially and adversely impact our clinical trials, business, financial condition and results of

Potential disruptions include but are not limited to:

or difficulties in enrolling patients in clinical trials and obtaining the results of completed

clinical trials;

rates of patients withdrawing from clinical trials following enrollment as a result of quarantine

or public health concerns;

of healthcare resources away from the conduct of clinical trials;

in prospective clinical trial collaborations with pharmaceutical companies and sponsors;

● interruption

or delays in the operations of the FDA or other regulatory authorities, which may impact

review and approval timelines;

● limitations

on our ability to recruit and hire key personnel due to our inability to meet with candidates

because of travel restrictions;

● limitations

on employee resources that would otherwise be focused on the conduct of clinical trials and

research as a result of focus on health matters and loss of productivity from remote work.

Related to Product Development and Product Regulation

we are unable to obtain approval from the FDA or comparable foreign regulatory authorities to market our products for their intended

use, we will not be able to generate revenue.

For a new drug to be approved for marketing, the FDA and other regulatory authorities must

determine that the drug is safe and effective.

Because all drugs can have adverse effects, the data from our Phase 3 clinical study must

demonstrate to the satisfaction of the FDA and other health authorities that the benefits of gedatolisib in combination with fulvestrant,

and with or without palbociclib, or gedatolisib in combination with fulvestrant plus a CDK4/6 inhibitor, outweigh its risks.

to demonstrate sufficient magnitude of benefit, even if the benefit is found to be statistically significant, may not support regulatory

marketability of our products, particularly gedatolisib, depends on securing approval from the FDA and equivalent foreign regulatory

This requires rigorous pre-clinical and clinical studies, including Phase 3 clinical trials for each intended use, that the benefits

of the therapy outweigh its risks.

Failure to demonstrate sufficient magnitude of benefit, even if the benefit is found to be statistically

significant, may not support regulatory approval.

Satisfaction of the FDA’s regulatory requirements typically takes many years

and requires substantial resources for research, development and testing.

a drug meets its primary efficacy endpoint objective in a Phase 3 clinical trial, and the drug sponsor has additional nonclinical and

clinical data required by the FDA or other regulatory authorities, the drug sponsor may submit an NDA seeking marketing approval.

submission of an NDA, these health authorities perform a benefit-risk assessment that considers the strength and quality of evidence

available and takes remaining uncertainties into account.

These considerations include an assessment of the strengths and limitations

of clinical trials, including design, and potential implications for assessing drug efficacy, the magnitude of benefit and interpretation

of clinical importance, the benefit attributed to the drug when studied in combination with other therapies, and the clinical relevance

of the study endpoints.

We are currently conducting a Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with

fulvestrant with or without palbociclib, in patients with HR+/HER2-

ABC after progression on CDK4/6 therapy , conducting a Phase 3 clinical

trial, VIKTORIA-2, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant

as first-line treatment for patients with endocrine treatment resistant HR+/HER2- ABC, and conducting a Phase 1b/2 clinical trial,

CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer.

In November 2025, we completed our NDA submission to the FDA for gedatolisib in HR+/HER2- ABC based

on clinical data from the PIK3CA WT cohort of the Phase 3 VIKTORIA-1 clinical trial.

On January 16, 2026, the FDA accepted our

NDA, designated it for Priority Review, and identified July 17, 2026 as our PDUFA target goal date.

have sought feedback from the FDA and other regulatory authorities on the design of gedatolisib clinical trials, with the goal of addressing

these considerations in the clinical trials’ design.

However, due to the complexity of clinical trials, the uncertainty of outcomes,

and the uncertainty of how the FDA and other regulatory authorities may balance benefits and risks in their review of an NDA, it may

not be practical or possible to address all benefit-risk assessment considerations in a clinical trial so that sufficient evidence is

generated to support a marketing approval, even if the primary endpoint objective is achieved in the Phase 3 stage of the trial.

FDA or other regulatory authorities may require us to redesign or conduct additional unplanned clinical trials before granting any approval

and we may not get approval at all.

Regulatory approval may

also be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that occur

during our regulatory review.

We cannot predict whether our research and clinical approaches will result in a drug that the FDA considers

safe for humans and effective for indicated uses.

regulatory approvals are delayed or not obtained, especially with respect to gedatolisib, it will negatively impact our ability to commercialize

our products and generate revenue and may diminish any

competitive advantages that we may otherwise enjoy .

If we are required to conduct additional clinical

trials or other testing of gedatolisib beyond those that we currently contemplate, if we are unable to successfully complete clinical

trials or other testing of gedatolisib, or if the results of these trials or tests are not positive or are only modestly positive or

if there are safety concerns, we may:

delayed in obtaining marketing approval, supplemental marketing approval, or

not obtain marketing approval at all;

approval for indications or patient populations that are not as broad as intended or desired;

approval with labeling that includes significant use or distribution restrictions or safety

warnings, including boxed warnings;

subject to changes in the way our products are administered;

required to perform additional clinical trials to support approval or be subject to additional

post-marketing testing requirements;

regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions

on its distribution in the form of the FDA’s REMS program or through modification to an existing REMS;

damage to our reputation.

Additionally,

if the size of the FDA group dedicated to reviewing oncology-related submissions is reduced, further delays of our regulatory

submissions may be encountered.

Therapy Designation, Fast Track Designation, NDA submission via RTOR, and being awarded Priority Review from the FDA may not actually

lead to a faster development or regulatory review or approval process.

a drug is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address

unmet medical needs for this condition, the product sponsor may apply for Fast Track Designation.

The designation offers the opportunity

for frequent interactions with the FDA to discuss the drug’s development plan and to ensure collection of appropriate data needed

to support drug approval, as well as eligibility for submission of an NDA.

addition, a drug may receive Breakthrough Therapy Designation if it is intended, alone or in combination with one or more other products,

to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate

substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects

observed early in clinical development.

The benefits of Breakthrough Therapy Designation include more intensive guidance from the FDA

on an efficient development program, access to a scientific liaison to help accelerate review time, and potential eligibility for Priority

Review if relevant criteria are met.

This designation can expedite the development and regulatory review of an investigational medicine

that is intended to treat a serious or life-threatening condition.

Track and Breakthrough Therapy Designations, as well as seeking to submit our NDA on a rolling basis pursuant to the FDA’s RTOR

program, and receiving Priority Review, are within the discretion of the FDA.

The FDA has granted both designations to our lead drug

candidate, gedatolisib, and has accepted our NDA which was filed via RTOR and designated it for Priority Review.

However, such designations

and programs may not result in a faster development process, review or approval compared to products considered for approval under conventional

FDA review procedures, and none of these designations and awards assures ultimate approval by the FDA.

In addition, the FDA may later

decide that the product no longer meets the qualification conditions and may rescind such designations or programs, or the FDA may not

approve our NDA by the Priority Review PDUFA target goal date of July 17, 2026.

and maintaining FDA approval of our product candidates in the U.S.

does not mean that we will be successful in obtaining regulatory approval

of our product candidates in other jurisdictions.

and maintaining FDA approval of our product candidates in the U.S.

does not guarantee that we will be able to obtain or maintain regulatory

approval in any other jurisdiction, while a failure or delay in obtaining FDA approval in the U.S.

may have a negative effect on the

regulatory approval process in other jurisdictions.

For example, even if the FDA grants marketing approval of a product candidate, a

comparable foreign regulatory authority must also approve the manufacturing, marketing and promotion of the product candidate in those

procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than,

those in the U.S., including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may

not be accepted by regulatory authorities in other jurisdictions.

In many jurisdictions outside the U.S., a product candidate must be

approved for reimbursement before it can be approved for sale in that jurisdiction.

In some cases, the price that we intend to charge

for our products is also subject to approval.

foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and

costs for us and could delay or prevent the introduction of our products in certain countries.

If we fail to comply with the regulatory

requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability

to realize the full market potential of our product candidates will be harmed.

if we receive initial regulatory approvals, we will be subject to ongoing regulatory obligations and continued regulatory review, which

may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or

experience unanticipated problems with our product candidates.

any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging,

storage, distribution, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety and

other post-marketing information, including both federal and state requirements in the U.S.

and requirements of comparable foreign regulatory

In addition, we will be subject to continued compliance with requirements for any clinical trials that we conduct post-approval.

Manufacturers

and manufacturers’ facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements.

Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including

manufacturing, production and quality control.

regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which

the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing,

including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate.

Certain endpoint data

we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or secondary endpoint

data such as patient-reported outcome measures.

The FDA may impose consent decrees or withdraw approval if compliance with regulatory

requirements and standards is not maintained or if problems occur after the product reaches the market.

Later discovery of previously

unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party

manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved

labeling to add new safety information, imposition of post-marketing studies or clinical trials to assess new safety risks or imposition

of distribution restrictions or other restrictions under a REMS program.

Other potential consequences include, among other things:

● restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory

product recalls;

● fines, warning letters or holds on clinical trials;

● refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation

of license approvals;

● product seizure or detention or refusal to permit the import or export of our product candidates;

● injunctions or the imposition of civil or criminal penalties.

The FDA strictly regulates marketing, labeling, advertising

and promotion of products that are placed on the market.

Products may be promoted only for the approved indications and in accordance

with the provisions of the approved label.

If we are slow or unable to adapt to changes in existing requirements or adopt new requirements

or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and

we may not achieve or sustain profitability.

Our focus on the clinical development of gedatolisib has led us to

minimize the Company’s activities to support development of CELsignia, which will significantly delay, or potentially forestall,

further advancement of clinical development of CELsignia tests or finding appropriate pharmaceutical company partners.

The success of our CELsignia tests depends on our

ability to attract pharmaceutical company partnerships that provide revenue from the sale of CELsignia tests during clinical trials, from

milestone payments during clinical trials, from sales of our CELsignia tests as companion diagnostics or stand-alone tests thereafter,

and, potentially, from royalties on the incremental drug revenues our tests enable.

Our ability to obtain such partnerships and generate

such revenue depends in part on the ability of our first CELsignia tests to demonstrate the potential incremental opportunity available

for pharmaceutical companies, as well as our ability to establish strategic partnerships or other arrangements with suitable pharmaceutical

Since these activities are no longer a priority for the Company, further advancement of the clinical development of the CELsignia

platform will be substantially delayed or forestalled.

Risks Related to Intellectual Property

We depend on intellectual property licensed from third parties, including

from Pfizer for our lead product candidate, and termination of this license could result in the loss of significant rights, which would

harm our business.

We are dependent on patents, know-how and proprietary

technology, both our own and licensed from others.

All patents covering gedatolisib and any combination therapies using our product candidates

are licensed from third parties.

Any termination of a product license could result in the loss of significant rights and would cause material

adverse harm to our ability to commercialize our product candidates.

Disputes may also arise between us and our licensors

regarding intellectual property subject to a license agreement, including:

● the scope of rights granted under the license agreement and other interpretation-related issues;

● whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject

to the licensing agreement;

● our right to sublicense patent and other rights to third parties under collaborative development relationships;

● our diligence obligations with respect to the use of licensed technology in relation to our development and commercialization of our

product candidates and what activities satisfy those diligence obligations;

● the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us

and our partners.

If disputes over intellectual property that we have

licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully

develop and commercialize the affected product candidates.

We are generally also subject to all of the same risks

with respect to protection of intellectual property that we own, as we are for intellectual property that we license.

If we or our licensors

fail to adequately protect this intellectual property, our ability to commercialize products could materially suffer.

If we fail to comply with our obligations under our patent license

with Pfizer, we could lose license rights that are important to our business.

We are a party to a license agreement with Pfizer

pursuant to which we in-license key patents for gedatolisib.

This license imposes various diligence, milestone payment, royalty, insurance

and other obligations on us.

If we fail to comply with these obligations, Pfizer may have the right to terminate the license, in which

event we would not be able to develop or market the products covered by such licensed intellectual property.

Further, we cannot be certain

that the activities by these licensors were conducted in compliance with applicable laws and regulations or will result in additional

valid and enforceable patents and other intellectual property rights.

We may not be successful in obtaining or maintaining necessary rights

to develop any future product candidates on acceptable terms.

Our clinical trials and other programs currently,

and may in the future, involve additional product candidates that require the use of, or reliance on, proprietary rights held by third

Accordingly, the growth of our business depends in part on our ability to acquire, in-license or use these proprietary rights.

We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights

from third parties that we identify as necessary or important to our business operations.

We may fail to obtain any of these licenses

at a reasonable cost or on reasonable terms, if at all, which could harm our business.

We may need to cease use of the compositions or

methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe

on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives,

which may not be feasible.

Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to

the same technologies licensed to us.

In that event, we may be required to expend significant time and resources to develop or license

replacement technology.

The licensing and acquisition of third-party intellectual

property rights is a competitive area, and companies that may be more established or have greater resources than we do may also be pursuing

strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize

our product candidates.

More established companies may have a competitive advantage over us due to their size, cash resources and greater

clinical development and commercialization capabilities.

There can be no assurance that we will be able to successfully complete such

negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may

seek to acquire.

If we are not able to prevent disclosure of our trade secrets and

other proprietary information, the value of our products could be significantly diminished.

We rely on trade secret protection to protect our

interests in proprietary know-how and in processes for which patents are difficult to obtain or enforce.

We may not be able to protect

our trade secrets adequately.

We have a policy of requiring our consultants, advisors and strategic partners to enter into confidentiality

agreements and our employees to enter into invention, non-disclosure and non-compete agreements.

However, no assurance can be given that

we have entered into appropriate agreements with all parties that have had access to our trade secrets, know-how or other proprietary

There is also no assurance that such agreements will provide meaningful protection of our trade secrets, know-how or other

proprietary information in the event of any unauthorized use or disclosure of information.

Furthermore, we cannot provide assurance that

any of our employees, consultants, contract personnel, or strategic partners, either accidentally or through willful misconduct, will

not cause serious damage to our programs and/or our strategy, for example by disclosing important trade secrets, know-how or proprietary

information to our competitors.

It is also possible that our trade secrets, know-how or other proprietary information could be obtained

by third parties as a result of breaches of our physical or electronic security systems.

Any disclosure of confidential data into the

public domain or to third parties could allow our competitors to learn our trade secrets and use the information in competition against

In addition, others may independently discover our trade secrets and proprietary information.

Any action to enforce our rights is

likely to be time consuming and expensive, and may ultimately be unsuccessful, or may result in a remedy that is not commercially valuable.

These risks are accentuated in foreign countries where laws or law enforcement practices may not protect proprietary rights as fully as

in the United States.

Any unauthorized disclosure of our trade secrets or proprietary information could harm our competitive position.

We may be subject to claims by employees claiming ownership of what

we regard as our own intellectual property.

While it is our policy to require our employees and

contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property

to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard

Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against

third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.

If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property

rights or personnel.

Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial

costs and be a distraction to management.

If we are unable to obtain and maintain intellectual property protection

for our product candidates, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors

could develop and commercialize product candidates similar or identical to ours, and our ability to successfully commercialize our product

candidates may be impaired.

We have applied for patents that protect our product

candidates, and our patent portfolio currently includes, for CELsignia, six issued U.S.

patents and 30 issued international patents, and,

for our drug candidate gedatolisib, 12 granted patents in the U.S.

and more than 290 patents granted in foreign jurisdictions including

Australia, Canada, China, France, Germany, Spain, United Kingdom and Japan.

We cannot ensure that our intellectual property position will

not be challenged or that all patents for which we have applied will be granted.

We cannot know with certainty whether we were the first

to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for

patent protection of such inventions.

The patent prosecution

process is expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable

patent applications at a reasonable cost or in a timely manner, or in all jurisdictions.

We may choose not to seek patent protection for

certain innovations and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions,

patents or other intellectual property rights may be unavailable or limited in scope.

Additionally, the laws and regulations governing

patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and

patents that we might obtain in the future.

There also may be patent reforms in foreign jurisdictions that could increase the uncertainties

and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents in those jurisdictions.

It is also possible that we will fail to identify patentable aspects of our discovery and nonclinical development output before it is

too late to obtain patent protection.

As a result of these factors, the issuance, scope,

validity, enforceability and commercial value of our patent rights are highly uncertain.

Our pending and future patent applications may

not result in patents being issued that protect our product candidates, in whole or in part, or which effectively prevent others from

commercializing competitive product candidates.

Moreover, given the amount of time required for the development, testing and regulatory

review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.

As a result, our owned patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar

or identical to ours.

Third parties may initiate legal proceedings alleging that we are

infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the

success of our business.

The commercial success of our products depends upon

our ability to use proprietary technologies without infringing the proprietary rights of third parties.

There is considerable intellectual

property litigation in the medical technology, biotechnology and pharmaceutical industries.

We may become party to, or threatened with,

future adversarial proceedings or litigation regarding intellectual property rights with respect to our products.

Additionally, because

current and future employees may have been previously employed at universities or other biotechnology, diagnostic technology or pharmaceutical

companies, including our competitors or potential competitors and strategic partners, third parties may assert infringement claims against

us based on existing patents or patents that may be granted in the future, or they may allege that our employees or we have used or disclosed

intellectual property, including trade secrets or other proprietary information, of any such employee’s former employer.

may be necessary to defend against these claims.

Patent litigation could result in loss of exclusivity

or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our

ability to stop others from using or commercializing similar or identical technology and product candidates, or limit the duration of

the patent protection of our technology and potential diagnostic tests.

If we are found to infringe a third party’s intellectual

property rights, we could be required to obtain additional licenses from such third party to continue developing and marketing our applicable

● restrictions

on the marketing or manufacturing of our products, withdrawal of the product from the market

or voluntary or mandatory product recalls;

warning letters or holds on clinical trials;

by the FDA to approve pending applications or supplements to approved applications filed

by us or suspension or revocation of license approvals;

seizure or detention or refusal to permit the import or export of our product candidates;

● injunctions

or the imposition of civil or criminal penalties.

FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market.

Products may be promoted

only for the approved indications and in accordance with the provisions of the approved label.

If we are slow or unable to adapt to changes

in existing requirements or adopt new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose

any marketing approval that we may have obtained and we may not achieve or sustain profitability.

Related to Commercializing Our Products

if our products achieve requisite approvals, they may fail to achieve the degree of market acceptance by physicians, patients, third-party

payors and others in the medical community necessary for commercial success.

any product we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients,

third-party payors and others in the medical community.

For example, existing drug therapies may be viewed as more reliable or more easily

administered than gedatolisib.

If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate

significant product revenues and we may not become profitable.

The degree of market acceptance of any product candidate, if approved

for commercial sale, will depend on a number of factors, including:

and potential advantages compared to alternatives;

ability to offer our products, if approved, for sale at acceptable prices;

● convenience

and ease of administration compared to other treatments;

willingness of the target patient population to try new therapies and of physicians to prescribe

or initiate these therapies;

strength of marketing and distribution support;

ability to obtain sufficient third-party coverage, market access and adequate reimbursement;

prevalence and severity of any side effects.

our products do not achieve an adequate level of acceptance, we may never generate significant product revenues and we may not become

we commercialize any product candidates, we will be subject to U.S.

and foreign governmental regulations as well as private payor policies

that mandate price controls or limitations on patient access to our products or establish prices paid by government entities or programs

for our products.

Our business and our future results could be adversely affected by changes in such regulations.

if we or our partners are successful in obtaining marketing approval, commercial success of any approved products will also depend in

large part on the availability of insurance coverage and adequate reimbursement from third-party payors, including government payors

such as the VA, Medicare and Medicaid programs, 340B, and managed care organizations in the U.S.

or country specific governmental organizations

in foreign countries.

Government and private payors routinely seek to manage utilization and control costs, and there is considerable

public and government scrutiny of pharmaceutical pricing.

Efforts by states and the federal government to regulate prices or payment

for pharmaceutical products, including proposed actions to facilitate drug importation, limit reimbursement to lower international (i.e.,

most favored nation) reference prices, require deep discounts, and require manufacturers to report and make public price increases and

sometimes provide a written justification for such price increases, could adversely affect our business if and as implemented.

of reimbursement may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare, including

the Inflation Reduction Act, which requires manufacturers of certain drugs to engage in price negotiations with Medicare, imposes rebates

under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation, and replaces the Part D coverage gap discount

program with a new discounting program.

Some states have implemented, and others are considering implementing, patient access constraints

or cost cutting under the Medicaid program, and some are considering measures that would apply to broader segments of their populations

that are not Medicaid-eligible.

State legislatures also have continued to focus on addressing drug costs, generally by increasing price

transparency or limiting drug price increases.

payors also could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product

and appropriateness for specific patient populations, to qualify for reimbursement, which could be costly and divert our resources.

government and other healthcare payors do not provide coverage and adequate reimbursement for our products once approved, market acceptance

and commercial success would be reduced.

Even if coverage is provided, the approved reimbursement amount may not be high enough to support

pricing that results in a sufficient return on our research and development investment.

expect pricing pressures will continue globally.

and foreign governmental regulations that mandate price controls or limitations

on patient access to our products or establish prices paid by government entities or programs for our products could impact our business,

and our future results could be adversely affected by changes in such regulations or policies.

may encounter difficulties in scaling production of, commercializing, marketing and distributing our products, including in hiring and

retaining a qualified sales force.

order to commercialize any of our products in the U.S.

and other jurisdictions, we must build production, marketing, sales, managerial

and other non-technical capabilities, or make arrangements with third parties to perform these services, and we may not be successful

These activities will be expensive and time-consuming and will require significant attention of our executive officers to

There are risks and material costs involved in establishing our own sales and marketing capabilities, as well as with entering

into arrangements with third parties to perform these services.

particular, there is intense competition for qualified sales personnel and our inability to hire or retain an adequate number of sales

representatives could limit our ability to maintain or expand our business and increase sales.

Furthermore, there is no guarantee that

the market opportunity for gedatolisib will be as significant as we expect or exist at all.

If we are unable to successfully commercialize

our products in the U.S.

or other jurisdictions, or if we are delayed in doing so, including if we are unable to develop our marketing

and sales networks or if our sales personnel do not perform as expected, we may never generate any revenue and our business may fail.

business, operational and financial goals may not be attainable if the market opportunities for our products are smaller than we expect.

Our internal research and third-party estimates may not accurately reflect the market opportunities for gedatolisib today or in the future.

total market opportunities that we believe exist are based on a variety of assumptions and estimates, including the size of the addressable

patient population in applicable jurisdictions, other available drugs in these markets, payor coverage, anticipated reimbursement, and

the price we will be able to charge for our products.

In addition, we have relied on third-party publications, research, surveys and

studies for information related to determining market opportunities, including without limitation, information on the number of addressable

cancer patients and those receiving various forms of treatment, the cost of drug therapy, the amount of revenue generated from various

types of drug therapy, the objective response rates of drug therapies, the number of deaths caused by cancer and the expected growth

in cancer drug therapy.

Our internal research and estimates on market opportunities have been verified by independent sources, but any

or all of our assumptions and/or estimates may prove to be incorrect for several reasons, such as inaccurate reports or information that

we have relied on, potential patients or providers not being amenable to using our products or such patients becoming difficult to identify

and access, limited reimbursement for our products, pricing pressure due to availability of alternative drugs or an inability to obtain

the necessary regulatory approvals for new indications.

If any or all of our assumptions and estimates prove inaccurate, we may not attain

our business, operational and financial goals.

Related to Intellectual Property

depend on intellectual property licensed from Pfizer for our lead product candidate, and termination of

this license could result in the loss of significant rights, which would materially and adversely impact our business.

are dependent on patents and know-how, both our own and licensed from Pfizer.

Key patents covering gedatolisib

and any combination therapies using our product candidates are licensed from Pfizer pursuant to the Gedatolisib License Agreement.

termination of the product license could result in the loss of significant rights and would cause material adverse harm to our ability

to commercialize our product candidates.

may also arise between us and Pfizer regarding intellectual property subject to the Gedatolisib License Agreement, including:

scope of rights granted under the license agreement and other interpretation-related issues;

and the extent to which our product candidates and processes infringe on intellectual property

of the licensor that is not subject to the license agreement;

right to sublicense patent and other rights to third parties under collaborative development

relationships;

diligence obligations with respect to the use of licensed assets in relation to our development

and commercialization of our product candidates and what activities satisfy those diligence

ownership of inventions and know-how resulting from the joint creation or use of intellectual

property by our licensors and us and our partners.

disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements

on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.

are generally also subject to all of the same risks with respect to protection of intellectual property that we own, as we are for intellectual

property that we license.

If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize

products could materially suffer.

we fail to comply with our obligations under our patent license with Pfizer, we could lose license rights that are important to our business.

are a party to a license agreement with Pfizer pursuant to which we in-license key patents for gedatolisib.

This license imposes various

diligence, milestone payment, royalty, insurance and other obligations on us.

If we fail to comply with these obligations, Pfizer may

have the right to terminate the license, in which event we would not be able to develop or market the products covered by such licensed

intellectual property.

Further, we cannot be certain that the activities conducted by Pfizer, or its predecessors, were performed in

compliance with applicable laws and regulations or will result in additional valid and enforceable patents and other intellectual property

may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.

clinical trials and other programs currently, and may in the future, involve additional product candidates that require the use of, or

reliance on, proprietary rights held by third parties.

Accordingly, the growth of our business depends in part on our ability to acquire,

in-license or use these proprietary rights.

We may be unable to acquire or in-license any compositions, methods of use, processes or

other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations.

We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which could harm our business.

may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to

develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development

delays, even if we were able to develop such alternatives, which may not be feasible.

Even if we are able to obtain a license, it may

be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.

In that event, we may be required to

expend significant time and resources to develop or license replacement technology.

licensing and acquisition of third-party intellectual property rights is a competitive area, and companies that may be more established

or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that

we may consider necessary or attractive in order to commercialize our product candidates.

More established companies may have a competitive

advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.

no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property

surrounding the additional product candidates that we may seek to acquire.

we are not able to prevent disclosure of our trade secrets and other proprietary information, the value of our products could be significantly

rely on trade secret protection to protect our interests in proprietary know-how and in processes for which patents are difficult to

obtain or enforce.

We may not be able to protect our trade secrets adequately.

We have a policy of requiring our consultants, advisors

and strategic partners to enter into confidentiality agreements and our employees to enter into invention, non-disclosure and restrictive

covenant agreements.

However, no assurance can be given that we have entered into appropriate agreements with all parties that have had

access to our trade secrets, know-how or other proprietary information.

There is also no assurance that such agreements will provide

meaningful protection of our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure

of information.

Furthermore, we cannot provide assurance that any of our employees, consultants, contract personnel, or strategic partners,

either accidentally or through willful misconduct, will not cause serious damage to our programs and/or our strategy, for example by

disclosing important trade secrets, know-how or proprietary information to our competitors.

It is also possible that our trade secrets,

know-how or other proprietary information could be obtained by third parties as a result of breaches of our physical or electronic security

Any disclosure of confidential data into the public domain or to third parties could allow our competitors to learn our trade

secrets and use the information in competition against us.

In addition, others may independently discover our trade secrets and proprietary

Any action to enforce our rights is likely to be time consuming and expensive, and may ultimately be unsuccessful, or may

result in a remedy that is not commercially valuable.

These risks are accentuated in foreign countries where laws or law enforcement

practices may not protect proprietary rights as fully as in the United States.

Any unauthorized disclosure of our trade secrets or proprietary

information could harm our competitive position.

may be subject to claims by employees claiming ownership of what we regard as our own intellectual property.

it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute

agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact

develops intellectual property that we regard as our own.

Our and their assignment agreements may not be self-executing or may be breached,

and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of

what we regard as our intellectual property.

If we fail in prosecuting or defending any such claims, in addition to paying monetary damages,

we may lose valuable intellectual property rights or personnel.

Even if we are successful in prosecuting or defending against such claims,

litigation could result in substantial costs and be a distraction to management.

we are unable to obtain and maintain intellectual property protection for our product candidates, or if the scope of the intellectual

property protection obtained is not sufficiently broad, our competitors could develop and commercialize product candidates similar or

identical to ours, and our ability to successfully commercialize our product candidates may be impaired.

have applied for patents that protect our product candidates, and our patent portfolio for our drug candidate, gedatolisib, includes

13 issued patents in the U.S.

and more than 297 patents granted in numerous foreign jurisdictions.

We cannot ensure that our intellectual

property position will not be challenged or that all patents for which we have applied will be granted.

We cannot know with certainty

whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we

were the first to file for patent protection of such inventions.

patent prosecution process is expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all

necessary or desirable patent applications at a reasonable cost or in a timely manner, or in all jurisdictions.

We may choose not to

seek patent protection for certain innovations and may choose not to pursue patent protection in certain jurisdictions, and under the

laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope.

Additionally, the

laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce

our existing patents and patents that we might obtain in the future.

There also may be patent reforms in foreign jurisdictions that could

increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued

patents in those jurisdictions.

It is also possible that we will fail to identify patentable aspects of our discovery and nonclinical

development output before it is too late to obtain patent protection.

a result of these factors, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.

Our pending and future patent applications may not result in patents being issued that protect our product candidates, in whole or in

part, or which effectively prevent others from commercializing competitive product candidates.

Moreover, given the amount of time required

for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before

or shortly after such candidates are commercialized.

As a result, our owned patent portfolio may not provide us with sufficient rights

to exclude others from commercializing products similar or identical to ours.

parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would

be uncertain and could have a material adverse effect on the success of our business.

commercial success of our products depends upon our ability to manufacture, market and sell our products without infringing the proprietary

rights of third parties.

There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries.

may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect

to our products.

Additionally, because current and future employees may have been previously employed at universities or other biotechnology,

diagnostic technology or pharmaceutical companies, including our competitors or potential competitors and strategic partners, third parties

may assert infringement claims against us based on existing patents or patents that may be granted in the future, or they may allege

that our employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any

such employee’s former employer.

Litigation may be necessary to defend against these claims.

litigation could result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable,

in whole or in part, which could limit our ability to stop others from using or commercializing similar product candidates, or limit

the duration of the patent protection of our products.

If we are found to infringe a third party’s intellectual property rights,

we could be required to obtain additional licenses from such third party to continue developing and marketing our applicable products.

However, we may not be able to obtain any required license on commercially reasonable terms or at all.

Even if we were able

to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.

be forced, including by court order, to cease commercializing the infringing technology or product.

In addition, we could be found liable for monetary

damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a patent.

A finding of infringement

could prevent us from commercializing our products or force us to cease some of our business operations, which could materially harm our

Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative

impact on our business.

Any lawsuits relating to infringement of intellectual property rights

necessary to defend ourselves or enforce our rights will be costly and time consuming and could be unsuccessful.

Because competition in our industry is intense, competitors

may infringe or otherwise violate our issued patents, patents of our licensors or other intellectual property.

To counter infringement

or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming, and could distract our

technical and management personnel from their normal responsibilities.

Any claims we assert against perceived infringers could provoke

these parties to assert counterclaims against us alleging that we infringe their patents.

In addition, in a patent infringement proceeding,

a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly

or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.

An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly.

We may also elect to enter into license agreements in order to settle patent infringement claims or to resolve disputes prior to litigation,

and any such license agreements may require us to pay royalties and other fees that could be significant.

Furthermore, because of the

substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential

information could be compromised by disclosure.

Risks Related to Our Reliance on Third Parties

We rely on third parties to conduct certain aspects of our preclinical

studies and clinical trials.

If these third parties do not successfully carry out their contractual duties, meet expected deadlines or

comply with regulatory requirements, we may not be able to obtain regulatory approval for, or commercialize, any potential product candidates.

We depend upon third parties to execute our operational

plans and to conduct certain aspects of our preclinical studies.

Additionally, we depend on third parties, including independent investigators,

to conduct our clinical trials, under agreements with universities, medical institutions, contract research organizations, or CROs, strategic

partners and others.

Our reliance on third parties may affect our development timelines and increase our costs.

We have limited control over third-party clinical

investigators and limited visibility into their day-to-day activities, including with respect to their compliance with the approved clinical

Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable

protocol, legal and regulatory requirements and scientific standards.

We and these third parties are required to comply with GCP requirements,

which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical

Regulatory authorities enforce these GCP requirements through periodic inspections of clinical trial sponsors, clinical investigators

and clinical trial sites.

If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated

in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or

terminate these trials or perform additional preclinical studies or clinical trials before approving our marketing applications.

our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and

regulations or healthcare privacy and security laws.

Any third parties conducting aspects of our preclinical

studies or our clinical trials will not be our employees and, except for remedies that may be available to us under our agreements with

such third parties, we cannot control whether or not they devote sufficient time and resources to our preclinical studies and clinical

These third parties may also have relationships with other commercial entities, including our competitors, for whom they may

also be conducting clinical trials or other product development activities, which could affect their performance on our behalf.

third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced

or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols

or regulatory requirements or for other reasons, our development timelines, including clinical development timelines, may be extended,

delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our

product candidates.

As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs

could increase and our ability to generate revenue could be delayed or precluded entirely.

Our reliance on third parties to formulate and manufacture our drug

product will expose us to risks that may delay the development, regulatory approval and commercialization of our drug product or result

in higher product costs.

We do not directly formulate or manufacture our drug

product candidate and do not intend to establish our own manufacturing facilities.

We will contract with one or more manufacturers to

manufacture and supply our drug product, and we will use other third parties to package, store and distribute drug supplies for our clinical

If our drug product receives FDA approval, we will rely on one or more third-party contractors to manufacture and distribute our

drug product.

Our reliance on a limited number of third-party manufacturers,

including one primary manufacturer of the active ingredient gedatolisib, exposes us to risks that, among other things, we may be unable

to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA must approve

any replacement or additional manufacturer;

our third-party manufacturers might be unable to formulate and manufacture our drugs in the

volume and of the quality required to meet our clinical and/or commercial needs, if any;

our contract manufacturers may not perform as

agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials, or to successfully

produce, store and distribute our products commercially;

and our contract manufacturers may fail to comply with good manufacturing practice

and other government regulations and corresponding foreign standards.

Each of these risks could delay our clinical trials, the approval,

if any, of our product candidates by the FDA, or the commercialization of our product candidates or result in higher costs or deprive

us of potential product revenues.

The pharmaceutical companies that we partner with for our CELsignia

tests may not be successful in receiving regulatory approval for drug indications or may not commercialize their companion therapies for

our expected companion diagnostic programs.

There can be no assurances that our pharmaceutical

partners for our CELsignia tests will be able to obtain regulatory approval for new indications to treat applicable patient populations

or otherwise be successful in commercializing their therapies.

Among other risks, our pharmaceutical company partners may not meet clinical

trial endpoint targets, may encounter regulatory or production delays, may not pursue commercialization of companion therapeutics, or

may terminate their relationship with us.

Performance issues or price increases by our shipping carriers could

adversely affect our business, results of operations and financial condition, and harm our reputation and ability to provide our products

on a timely basis.

Expedited, reliable shipping is essential to our operations.

Should our shipping carriers encounter delivery performance issues such as loss, damage or destruction of a sample, such occurrences may

damage our reputation and lead to decreased demand for our services and increased cost and expense to our business.

In addition, any significant

increase in shipping rates could adversely affect our operating margins and results of operations.

Similarly, strikes, severe weather,

natural disasters or other service interruptions by delivery services we use would adversely affect our ability to receive and process

patient samples on a timely basis.

There are only a few providers of overnight nationwide transport services, and there can be no assurance

that we will be able to maintain arrangements with providers on acceptable terms, if at all.

Risks Related to Commercializing Our Products

Even if our products achieve positive clinical trial results and

requisite approvals, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in

the medical community necessary for commercial success.

If any product we develop achieves positive clinical

trial results and receives marketing approval, whether on a standalone basis or in combination with other therapies, it may nonetheless

fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community.

existing drug therapies may be viewed as more reliable than gedatolisib.

If the product candidates we develop do not achieve an adequate

level of acceptance, we may not generate significant product revenues and we may not become profitable.

The degree of market acceptance

of any product candidate, if approved for commercial sale, will depend on a number of factors, including:

● efficacy and potential advantages compared to alternatives;

● the ability to offer our products, if approved, for sale at competitive prices;

● convenience and ease of administration compared to other treatments;

● the willingness of the target patient population to try new therapies or diagnostics and of physicians to prescribe or initiate these

● the strength of marketing and distribution support;

● the ability to obtain sufficient third-party coverage, market access and adequate reimbursement;

● the prevalence and severity of any side effects.

If our products do

not achieve an adequate level of acceptance, we may never generate significant product revenues and we may not become profitable.

If we commercialize any product candidates, we will be subject to

and foreign governmental regulations as well as private payor policies that mandate price controls or limitations on patient access

to our products or establish prices paid by government entities or programs for our products.

Our business and our future results could

be adversely affected by changes in such regulations.

Even if we or our partners are successful in obtaining

marketing approval, commercial success of any approved products will also depend in large part on the availability of insurance coverage

and adequate reimbursement from third-party payors, including government payors such as the VA, Medicare and Medicaid programs, 340B,

and managed care organizations in the U.S.

or country specific governmental organizations in foreign countries.

Government and private

payors routinely seek to manage utilization and control costs, and there is considerable public and government scrutiny of pharmaceutical

and diagnostic pricing.

Efforts by states and the federal government to regulate prices or payment for pharmaceutical products, including

proposed actions to facilitate drug importation, limit reimbursement to lower international reference prices, require deep discounts,

and require manufacturers to report and make public price increases and sometimes provide a written justification for such price increases,

could adversely affect our business if implemented.

Availability of reimbursement may be affected by existing

and future healthcare reform measures designed to reduce the cost of healthcare, including the Inflation Reduction Act, which requires

manufacturers of certain drugs to engage in price negotiations with Medicare, imposes rebates under Medicare Part B and Medicare Part

D to penalize price increases that outpace inflation, and replaces the Part D coverage gap discount program with a new discounting program.

Some states have implemented, and others are considering implementing, patient access constraints or cost cutting under the Medicaid program,

and some are considering measures that would apply to broader segments of their populations that are not Medicaid-eligible.

State legislatures

also have continued to focus on addressing drug costs, generally by increasing price transparency or limiting drug price increases.

Third-party payors also could require us to conduct

additional studies, including post-marketing studies related to the cost effectiveness of a product and appropriateness for specific patient

populations, to qualify for reimbursement, which could be costly and divert our resources.

If government and other healthcare payors do

not provide coverage and adequate reimbursement for our products once approved, market acceptance and commercial success would be reduced.

Even if coverage is provided, the approved reimbursement amount may not be high enough to support pricing that results in a sufficient

return on our research and development investment.

We expect pricing pressures will continue globally.

and foreign governmental regulations that mandate price controls or limitations on patient access to our products or establish prices

paid by government entities or programs for our products could impact our business, and our future results could be adversely affected

by changes in such regulations or policies.

We may encounter difficulties in scaling production of, commercializing,

marketing and distributing our products, including in hiring and retaining a qualified sales force.

In order to commercialize any of our products, we

must build production, marketing, sales, managerial and other non-technical capabilities or make arrangements with third parties to perform

these services, and we may not be successful in doing so.

Our beliefs that our products will be commercially viable have not been tested.

These activities will be expensive and time-consuming and will require significant attention of our executive officers to manage.

are risks involved in establishing our own sales and marketing capabilities, as well as with entering into arrangements with third parties

to perform these services.

In particular, there is intense competition for qualified

sales personnel and our inability to hire or retain an adequate number of sales representatives could limit our ability to maintain or

expand our business and increase sales.

Furthermore, there is no guarantee that the market opportunity for gedatolisib will be as significant

as we expect or exist at all.

If we are unable to

successfully commercialize our products, or if we are delayed in doing so, including if we are unable to develop our marketing and sales

networks or if our sales personnel do not perform as expected, we may never generate any revenue and our business may fail.

Our business, operational and financial goals may not be attainable

if the market opportunities for our products are smaller than we expect.

Our internal research and third party estimates may not accurately

reflect the market opportunities for gedatolisib today or in the future.

The total market opportunities that we believe exist

are based on a variety of assumptions and estimates, including the size of the addressable patient population in applicable jurisdictions,

the penetration of other drugs in these markets, the number of potential companion diagnostic programs we will be able to successfully

pursue, the amount of potential milestone payments that we could receive in companion diagnostic programs, the number of patients we will

test in clinical trials, the price we will be able to charge for our products and the total annual number of cancer patients with undiagnosed

abnormal cell signaling.

In addition, we have relied on third-party publications, research, surveys and studies for information related

to determining market opportunities, including without limitation, information on the number of cancer patients and those receiving various

forms of treatment, the cost of drug therapy, the amount of revenue generated from various types of drug therapy, the objective response

rates of drug therapies, the number of deaths caused by cancer and the expected growth in cancer drug therapy and diagnostic markets.

Our internal research and estimates on market opportunities have been verified by independent sources, but any or all of our assumptions

and/or estimates may prove to be incorrect for several reasons, such as inaccurate reports or information that we have relied on, potential

patients or providers not being amenable to using our products or such patients becoming difficult to identify and access, limited reimbursement

for our products, pricing pressure due to availability of alternative drugs or an inability to obtain the necessary regulatory approvals

for new indications.

If any or all of our assumptions and estimates prove inaccurate, we may not attain our business, operational and

financial goals.

Other Risks Related to Government Regulation for Our Business

Failure to comply with the HIPAA security and privacy regulations

may increase our operational costs.

A portion of the data that we obtain and handle for

or on behalf of our clients is considered protected health information, or PHI, subject to HIPAA.

Under HIPAA and our contractual agreements

with our HIPAA-covered entity health plan customers, we may be considered a “business associate” to those customers and are

required to maintain the privacy and security of PHI in accordance with HIPAA and the terms of our business associate agreements with

our clients, including by implementing HIPAA-required administrative, technical and physical safeguards.

We are also required to maintain

similar business associate agreements with our subcontractors that have access to PHI of our customers in rendering services to us or

on our behalf.

We will incur significant costs to establish and maintain these safeguards and, if additional safeguards are required to

comply with HIPAA regulations or our clients’ requirements, our costs could increase further, which would negatively affect our

operating results.

Furthermore, we cannot guarantee that such safeguards have been and will continue to be adequate under applicable laws.

If we have failed, or fail in the future, to maintain adequate safeguards, or we or our agents or subcontractors use or disclose PHI in

a manner prohibited or not permitted by HIPAA, our subcontractor business associate agreements, or our business associate agreements with

our customers, or if the privacy or security of PHI that we obtain and handle is otherwise compromised, we could be subject to significant

liabilities and consequences.

Compliance with global privacy and data security requirements could

result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply

with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business,

financial condition or results of operations.

In addition to PHI, we collect, receive, store, process,

use, generate, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share (collectively, process) personal data

and other sensitive information.

Accordingly, we are, or may become, subject to numerous federal, state, local and foreign privacy and

security laws regulating the collection, use, safeguarding, transfer and other processing of information.

Globally, virtually every jurisdiction in which we

operate has established its own data security and privacy frameworks with which we must comply.

For example, the collection, use, disclosure,

transfer, or other processing of personal data regarding individuals in the UK, and the European Economic Area (the “EEA”),

including personal health data, is subject to the UK/EU General Data Protection Regulation (the “GDPR”), which is wide-ranging

in scope and imposes numerous requirements on companies that process personal data, including requirements relating to the processing

of health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals

regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing

notification of data breaches, and taking certain measures when engaging third-party processors.

In addition, the GDPR also imposes strict

rules on the transfer of personal data to countries outside the UK/European Union, including the United States, and, as a result, increases

the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that

are considered to lack an adequate level of data protection, such as the United States.

The GDPR also permits data protection authorities

to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR,

which can be up to 4% of global revenue or €20 million, whichever is greater, and it also confers a private right of action on data

subjects and consumer associates to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for

damages resulting from violations of the GDPR.

In addition, the GDPR provides that UK/EU member states may make their own further laws

and regulations limiting the processing of personal data, including genetic, biometric or health data.

Given the breadth and depth of

changes in data protection obligations, preparing for and complying with these requirements is rigorous and time intensive and requires

significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service

providers, contractors or consultants that process or transfer personal data collected in the European Union.

Similar actions are either in place or underway in

the United States.

For example, the California Consumer Privacy Act of 2018 (the “CCPA”), as amended and expanded by the California

Privacy Rights Act (the “CPRA”), applies to personal information of consumers, business representatives, and employees, and

requires covered businesses to provide specific disclosures related to a business’s processing of personal data, new operational

practices, and requirements to respond to certain requests from California residents related to their personal data.

There is uncertainty

about how the CPRA and other similar laws may be implemented and applied, and inconsistencies across jurisdictions complicate our compliance

Accordingly, the CPRA and other similar laws may impact our business activities and increase our compliance costs, as well as

our legal risks.

The regulatory framework for the collection, use, safeguarding, transfer and other processing of information is rapidly

evolving and is likely to remain uncertain for the foreseeable future.

Evolving data privacy regulations may interrupt or

delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government

enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our

business, financial condition or results of operations.

Even if we are not determined to have violated these laws, government investigations

into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation

and our business.

We will also need to expend a considerable amount of resources complying

with other federal, state and foreign laws and regulations.

If we are unable to comply or have not complied with such laws, we could face

substantial penalties or other adverse actions.

Our operations are subject, directly or indirectly,

to other federal, state and foreign laws and regulations that are complex and their application to our specific products, services and

relationships may not be clear and may be applied to our business in ways that we do not anticipate.

Compliance with laws and regulations

will require us to expend considerable resources implementing internal policies and procedures for compliance and ongoing monitoring and

will require significant attention of our management team.

This will be challenging as an early-stage company with limited financial resources

and human capital.

Even if we were able to obtain

a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.

We could be forced,

including by court order, to cease commercializing the infringing technology or product.

addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully

infringed a patent.

A finding of infringement could prevent us from commercializing our products or force us to cease some of our business

operations, which could materially harm our business.

Claims that we have misappropriated the confidential information or trade secrets

of third parties could have a similar negative impact on our business.

lawsuits relating to infringement of intellectual property rights necessary to defend ourselves or enforce our rights will be costly

and time consuming and could be unsuccessful.

competition in our industry is intense, competitors may infringe or otherwise violate our issued patents, patents of our licensors or

other intellectual property.

To counter infringement or unauthorized use, we may be required to file infringement claims, which can be

expensive and time consuming, and could distract our technical and management personnel from their normal responsibilities.

we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their

In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole

or in part, construe the patent’s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds

that our patents do not cover the technology in question.

An adverse result in any litigation proceeding could put one or more of our

patents at risk of being invalidated or interpreted narrowly.

We may also elect to enter into license agreements in order to settle patent

infringement claims or to resolve disputes prior to litigation, and any such license agreements may require us to pay royalties and other

fees that could be significant.

Furthermore, because of the substantial amount of discovery required in connection with intellectual

property litigation, there is a risk that some of our confidential information could be compromised by disclosure.

Related to Our Reliance on Third Parties

rely on third parties to conduct certain aspects of our preclinical studies and clinical trials.

If these third parties do not successfully

carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory

approval for, or commercialize, any potential product candidates.

depend upon third parties to execute certain aspects of our operational plans and to conduct certain aspects of our preclinical studies.

Additionally, we depend on third parties, including independent investigators, to conduct our clinical trials, under agreements with

universities, medical institutions, CROs, strategic partners and others.

Our reliance on third parties may affect our development timelines

and increase our costs.

have limited control over third-party clinical investigators and limited visibility into their day-to-day activities, including with

respect to their compliance with the approved clinical protocol.

Nevertheless, we are responsible for ensuring that each of our clinical

trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards.

third parties are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign

regulatory authorities for product candidates in clinical development.

Regulatory authorities enforce these GCP requirements through

periodic inspections of clinical trial sponsors, clinical investigators and clinical trial sites.

If we or any of these third parties

fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the

FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional preclinical

studies or clinical trials before approving our marketing applications.

Moreover, our business may be adversely affected if any of these

third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.

third parties conducting aspects of our preclinical studies or our clinical trials will not be our employees and, except for remedies

that may be available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time

and resources to our preclinical studies and clinical programs.

These third parties may also have relationships with other commercial

entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which

could affect their performance on our behalf.

If these third parties do not successfully carry out their contractual duties or obligations

or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the preclinical or clinical data they obtain

is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons, our development timelines,

including clinical development timelines, may be extended, delayed or terminated and we may not be able to complete development of, obtain

regulatory approval of or successfully commercialize our product candidates.

As a result, our financial results and the commercial prospects

for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed or precluded

reliance on third parties to formulate, manufacture and distribute our drug product exposes us to risks that may delay the

development, regulatory approval and commercialization of our drug product or result in higher product and operational

do not directly formulate, manufacture or distribute our drug product candidate and do not intend to establish our own formulation,

manufacturing or distribution facilities.

We have contracted with third-party contract manufacturers to formulate, manufacture and

supply our drug product, and we use other third parties to package, store and distribute drug product for our clinical trials.

our drug product receives FDA approval, we will rely on one or more third-party contract manufacturers to manufacture and package

our commercial drug product, and we will use a 3PL to distribute our commercial drug product.

reliance on a limited number of third-party manufacturers, including one primary manufacturer of the active ingredient gedatolisib, exposes

us to risks that, among other things, we may be unable to identify manufacturers on acceptable terms or at all because the number of

potential manufacturers is limited and the FDA must approve any replacement or additional manufacturer;

our third-party manufacturers

might be unable to manufacture our drugs in the volume and of the quality required to meet our clinical and/or commercial needs, if any;

our contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to

supply our clinical trials, or to successfully produce, store and distribute our products commercially;

and our contract manufacturers

may fail to comply with good manufacturing practice and other government regulations and corresponding foreign standards.

Each of these

risks could delay our clinical trials, the approval, if any, of our product candidates by the FDA, or the commercialization of our product

candidates or result in higher costs or deprive us of potential product revenues.

issues or price increases by our shipping carriers could adversely affect our business, results of operations and financial condition,

and harm our reputation and ability to provide our products on a timely basis.

reliable shipping is essential to our operations.

Should our shipping carriers encounter delivery performance issues such as loss, damage

or destruction of our API or product, such occurrences may damage our reputation and adversely affect our business.

In addition, any

significant increase in shipping rates could adversely affect our operating margins and results of operations.

Similarly, strikes, severe

weather, natural disasters or other service interruptions by delivery services we use would adversely affect our ability to receive and

process product orders on a timely basis.

There are only a few providers of overnight nationwide transport services, and there can be

no assurance that we will be able to maintain arrangements with providers on acceptable terms, if at all.

Risks Related to Government Regulation for Our Business

to comply with applicable U.S.

data security and privacy regulations may increase our operational costs.

we are not a covered entity under HIPAA, and our clinical operations are exempt from most state and federal data protection

The personal data of clinical trial subjects collected by our CROs’ U.S.

clinical sites is considered protected

health information, or PHI, subject to the U.S.

sites’ compliance with HIPAA.

We will incur significant costs to establish and maintain data privacy

safeguards and, if we are required to comply with HIPAA or U.S.

state regulations in the future, our costs could increase

further, which would negatively affect our operating results.

Furthermore, we cannot guarantee that such safeguards have been and

will continue to be adequate under applicable laws.

we receive FDA approval and launch gedatolisib in the U.S., we expect to be subject to comprehensive state privacy laws.

example, the CCPA applies to personal information of

consumers, business representatives, and employees, and requires covered businesses to provide specific disclosures related to a

business’s processing of personal data, new operational practices, and requirements to respond to certain requests from

California residents related to their personal data.

New regulations and enforcement actions related to the CCPA and similar state

comprehensive privacy laws continue to impact how companies think about and establish compliance mechanisms across the U.S.

privacy compliance is further complicated by inconsistent state laws that require complex operational frameworks for full

Accordingly, the CCPA and other similar state laws may impact our business activities and increase our compliance costs,

as well as our legal risks.

The regulatory framework for the collection, use, safeguarding, transfer and other processing of

information is rapidly evolving and is likely to remain uncertain for the foreseeable future.

data privacy regulations may interrupt or delay our development, regulatory and commercialization activities and increase our cost

of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us

and could have a material adverse effect on our business, financial condition or results of operations.

Even if we are not determined

to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and

generate negative publicity, which could harm our reputation and our business.

with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect

and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which

may have a material adverse effect on our business, financial condition or results of operations.

CROs and clinical investigators involved in our clinical trials may collect, receive, store, process, use, generate, transfer, disclose,

make accessible, protect, secure, dispose of, transmit and share (collectively, “process”) personal data as defined in data protection

laws outside the U.S.

Accordingly, we are subject to numerous foreign privacy and security laws regulating the collection, use, safeguarding,

transfer and other processing of personal data.

Globally, virtually every jurisdiction in which we operate has established

its own data security and privacy frameworks with which we must comply.

For example, the collection, use, disclosure, transfer, or other

processing of personal data regarding individuals in the UK, the EU, and the EEA, is subject to the UK GDPR and EU GDPR (together, “UK/EU

GDPR”), which is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements

relating to the processing of health and other sensitive data, obtaining consent of the individuals to whom the personal data relates,

providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality

of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors.

the UK/EU GDPR also imposes strict rules on the transfer of personal data to countries outside the UK/EU/EEA, including the U.S., and,

as a result, increases the scrutiny that clinical trial sites located in the UK/EU/EEA should apply to transfers of personal data from

such sites to countries that are considered to lack an adequate level of data protection, such as the U.S.

The UK/EU GDPR also permits

data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines

for violations of the UK/EU GDPR, which can be up to 4% of global revenue or £17 million/€20 million, whichever is greater,

and it also confers a private right of action on data subjects and consumer associates to lodge complaints with supervisory authorities,

seek judicial remedies, and obtain compensation for damages resulting from violations of the UK/EU GDPR.

In addition, the UK/EU GDPR provides

that UK/EU/EEA member states may make their own further laws and regulations limiting the processing of personal data, including genetic,

biometric or health data.

Given the breadth and depth of changes in data protection obligations, preparing for and complying with these

requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices,

as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data

collected in the UK/EU/EEA.

data privacy regulations may interrupt or delay our development, regulatory and commercialization activities and increase our cost of

doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and

could have a material adverse effect on our business, financial condition or results of operations.

Even if we are not determined to

have violated these laws, government investigations into these issues typically require the expenditure of significant resources and

generate negative publicity, which could harm our reputation and our business.

will also need to expend a considerable amount of resources complying with other federal, state and foreign laws and regulations.

we are unable to comply or have not complied with such laws, we could face substantial penalties or other adverse actions.

operations are subject, directly or indirectly, to other federal, state and foreign laws and regulations that are complex and their application

to our specific products, services and relationships may not be clear and may be applied to our business in ways that we do not anticipate.

Compliance with laws and regulations will require us to expend considerable resources implementing internal policies and procedures for

compliance and ongoing monitoring and will require significant attention of our management team.

This will be challenging as an early-stage

company with limited financial resources and human capital.

These laws include, for example:

● Title XI of the Social Security Act, commonly referred to as the federal Anti-Kickback Statute, which prohibits the knowing and willful

offer, payment, solicitation or receipt of remuneration, directly or indirectly, in cash or in kind, in return for or to reward the referral

of patients or arranging for the referral of patients, or in return for the recommendation, arrangement, purchase, lease or order of items

or services that are covered, in whole or in part, by a federal healthcare program such as Medicare or Medicaid;

● The civil False Claims Act, which forbids the knowing submission or “causing the submission” of false or fraudulent information

or the failure to disclose information in connection with the submission and payment of claims for reimbursement to Medicare, Medicaid,

federal healthcare programs or private health plans;

● The federal Physician Self-referral Law, commonly known as the Stark Law, which prohibits physicians from referring Medicare or Medicaid

patients to providers of “designated health services” with whom the physician or a member of the physician’s immediate

family has an ownership interest or compensation arrangement, unless a statutory or regulatory exception applies, and similar state equivalents

that may apply regardless of payor;

XI of the Social Security Act, commonly referred to as the federal Anti-Kickback Statute,

which prohibits the knowing and willful offer, payment, solicitation or receipt of remuneration,

directly or indirectly, in cash or in kind, in return for or to reward the referral of patients

or arranging for the referral of patients, or in return for the recommendation, arrangement,

purchase, lease or order of items or services that are covered, in whole or in part, by a

federal healthcare program such as Medicare or Medicaid;

civil False Claims Act, which forbids the knowing submission or “causing the submission”

of false or fraudulent information or the failure to disclose information in connection with

the submission and payment of claims for reimbursement to Medicare, Medicaid, federal healthcare

programs or private health plans;

federal Physician Self-referral Law, commonly known as the Stark Law, which prohibits physicians

from referring Medicare or Medicaid patients to providers of ”designated health

services” with whom the physician or a member of the physician’s immediate family

has an ownership interest or compensation arrangement, unless a statutory or regulatory exception

applies, and similar state equivalents that may apply regardless of payor;

Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S.

domestic bribery statute contained in 18 U.S.C.

domestic bribery

statute contained in 18 U.S.C.

§ 201, the U.S.

Travel Act, and the USA PATRIOT Act, which among other things, prohibit companies and their employees, agents, third-party

intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly,

improper payments or benefits to recipients in the public or private sector.

Many states and foreign

governments have adopted similar laws and regulations.

Violations of law could subject us to civil or criminal penalties, monetary fines,

disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment

of our operations.

We could also be required to change or terminate some portions of operations or business or could be disqualified from

providing services to healthcare providers doing business with government programs.

Risks Relating to Our Common Stock

Provisions in our corporate charter

documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult

and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our certificate of incorporation and

our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider

favorable, including transactions in which you might otherwise receive a premium for your shares.

These provisions could also limit the

price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our

common stock.

In addition, because our board of directors will be responsible for appointing the members of our management team, these

provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult

for stockholders to replace members of our board of directors.

Among other things, these provisions:

● allow the authorized number of our directors to be changed only by resolution of our board of directors;

● limit the manner in which stockholders can remove directors from our board of directors;

● establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our

board of directors;

● require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by

written consent;

● limit who may call stockholder meetings;

● authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a “poison

pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have

not been approved by our board of directors;

● require the approval of the holders of at least two-thirds of the votes that all our stockholders would be entitled to cast to amend

or repeal specified provisions of our certificate of incorporation or bylaws.

Moreover, we are governed

by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding

voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired

in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

Any of these provisions of our charter documents or

Delaware law could, under certain circumstances, depress the market price of our common stock.

The price of our common stock may be volatile and fluctuate substantially,

which could result in substantial losses for purchasers of our common stock or could subject us to securities litigation.

Our stock price may be extremely volatile.

market in general and the market for smaller medical technology companies in particular have experienced extreme volatility that has often

been unrelated to the operating performance of particular companies.

As a result of this volatility, investors may not be able to sell

our common stock at or above the price they paid for such stock.

The market price for our common stock may be influenced by many factors,

● the success of competitive products or technologies;

● results of existing or future clinical trials;

● regulatory or legal developments in the United States and other countries;

● developments or disputes concerning patent applications, issued patents or other proprietary rights;

● the recruitment or departure of key personnel;

● the level of expenses related to any of our products or clinical development programs;

● actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

● operating results that fail to meet expectations of securities analysts that cover our company;

● variations in our financial results or those of companies that are perceived to be similar to us;

● changes in the structure of healthcare payment systems;

● market conditions in the pharmaceutical, biotechnology and medical technology sectors;

● sales of our stock by us, our insiders and our other stockholders;

● general economic and market conditions;

● the other factors described in this “Risk Factors” section.

Additionally, companies that have experienced volatility

in the market price of their stock have been subject to an increased incidence of securities class action litigation.

We may be the target

of this type of litigation in the future.

Securities litigation against us could result in substantial costs and divert our management’s

attention from other business concerns, which could seriously harm our business.

Future sales of shares of our common stock, including by us and significant

stockholders, could negatively affect our stock price.

Sales of a substantial number of shares of our common

stock in the public market could occur at any time.

Since December 2022, we have issued 5,340,914 shares of common stock pursuant to equity

financing arrangements, including pursuant to our Open Market Sale Agreement SM with Jefferies LLC, as agent, pursuant to which

we may offer and sell, from time to time, through Jefferies, shares of our common stock having an aggregate offering price of up to $125.0

At December 31, 2024, $125.0 million of common stock remains available for sale under the Jefferies agreement.

We may enter into

additional equity financing arrangements in the future.

Travel Act, and the USA PATRIOT Act,

which among other things, prohibit companies and their employees, agents, third-party intermediaries,

joint venture partners and collaborators from authorizing, promising, offering, or providing,

directly or indirectly, improper payments or benefits to recipients in the public or private

states and foreign governments have adopted similar laws and regulations.

Violations of law could subject us to civil or criminal penalties,

monetary fines, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings

and curtailment of our operations.

We could also be required to change or terminate some portions of operations or business or could

be disqualified from providing services to healthcare providers doing business with government programs.

at the FDA and other government agencies from funding cuts, personnel losses, leadership changes, regulatory reform, government shutdowns

and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development programs and develop

and secure approval of our product candidates in a timely manner, which would negatively impact our business.

FDA and comparable regulatory agencies in foreign jurisdictions, such as the EMA, play an important role in the development of our product

candidates by providing guidance on our clinical development programs and reviewing our regulatory submissions, including NDAs, INDs,

requests for special designations and marketing applications.

If these oversight and review activities are disrupted, then correspondingly

our ability to develop and secure timely approval of our product candidates could be impacted in a negative manner.

example, the loss of FDA leadership and personnel and new leadership at the U.S.

Department of Health & Human Services, the FDA and

the Center for Drug Evaluation and Research could lead to disruptions and delays in FDA guidance and review and approval of our product

Further, while the FDA’s review of marketing applications and other activities for new drugs is largely funded through

the user fee program established under PDUFA, it remains unclear how the administration’s recent reduction in force and budget

cuts will impact this program and the ability of the FDA to provide guidance and review our product candidate in a timely manner.

is also substantial uncertainty as to how regulatory reform measures being implemented by the Trump Administration across the government

will impact the FDA and other federal agencies with jurisdiction over our activities.

For example, since taking office, the President

has issued a number of executive orders that could have a significant impact on the manner in which the FDA conducts its operations and

engages in regulatory and oversight activities.

if any of the foregoing developments and others impact the ability of the FDA to provide us with guidance regarding our clinical development

programs or delay the agency’s review of our regulatory submissions, including the NDA we submitted in November 2025 that was accepted

by the FDA in January 2026, our business would be negatively impacted.

Relating to Our Common Stock

in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders,

more difficult and may prevent attempts by our stockholders to replace or remove our current management.

in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control

of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your

These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock,

thereby depressing the market price of our common stock.

In addition, because our board of directors will be responsible for appointing

the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our

current management by making it more difficult for stockholders to replace members of our board of directors.

Among other things, these

the authorized number of our directors to be changed only by resolution of our board of directors;

the manner in which stockholders can remove directors from our board of directors;

advance notice requirements for stockholder proposals that can be acted on at stockholder

meetings and nominations to our board of directors;

that stockholder actions must be effected at a duly called stockholder meeting and prohibit

actions by our stockholders by written consent;

who may call stockholder meetings;

our board of directors to issue preferred stock without stockholder approval, which could

be used to institute a “poison pill” that would work to dilute the stock ownership

of a potential hostile acquirer, effectively preventing acquisitions that have not been approved

by our board of directors;

the approval of the holders of at least two-thirds of the votes that all our stockholders

would be entitled to cast to amend or repeal specified provisions of our certificate of incorporation

we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess

of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction

in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed

of these provisions of our charter documents or Delaware law could, under certain circumstances, depress the market price of our common

price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our

common stock or could subject us to securities litigation.

stock price may be extremely volatile.

The stock market in general and the market for smaller medical technology companies in particular

have experienced extreme volatility that has often been unrelated to the operating performance of particular companies.

As a result of

this volatility, investors may not be able to sell our common stock at or above the price they paid for such stock.

The market price

for our common stock may be influenced by many factors, including:

success of competitive products or technologies;

of existing or future clinical trials;

or legal developments in the United States and other countries;

● developments

or disputes concerning patent applications, issued patents or other proprietary rights;

recruitment or departure of key personnel;

level of expenses related to any of our products or clinical development programs;

or anticipated changes in estimates as to financial results, development timelines or recommendations

by securities analysts;

results that fail to meet expectations of securities analysts that cover our company;

in our financial results or those of companies that are perceived to be similar to us;

in the structure of healthcare payment systems;

conditions in the pharmaceutical, biotechnology and medical technology sectors;

of our stock by us, our insiders and our other stockholders;

economic and market conditions;

other factors described in this “Risk Factors” section.

Additionally,

companies that have experienced volatility in the market price of their stock have been subject to an increased incidence of securities

class action litigation.

We may be the target of this type of litigation in the future.

Securities litigation against us could result

in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.

sales of shares of our common stock, including by us and significant stockholders, could negatively affect our stock price.

of a substantial number of shares of our common stock in the public market could occur at any time.

Since December 2023, we have issued

6,478,782 shares of common stock pursuant to equity financing arrangements, including pursuant to our Open Market Sale Agreement SM

with Jefferies LLC (“Jefferies”), as agent, pursuant to which we may currently offer and sell, from time to time, through

Jefferies, shares of our common stock having an aggregate offering price of up to $400.0 million, all of which remains available for

In addition, in August 2025, we issued and sold in a public offering $201.3 million aggregate principal amount of Notes, which

would result in the issuance of 3,923,002 shares if the Notes were converted in full as of December 31, 2025.

We may enter into additional

equity or convertible debt financing arrangements in the future.

The shares of common stock that we have issued pursuant to equity financings,

or may issue in the future, may be resold at any time in the discretion of the investors.

In addition, an aggregate of 14,444,709 shares of

common stock are issuable upon conversion or exercise of currently outstanding preferred stock and financing warrants, subject to certain

beneficial ownership limitations, which the investors may subsequently resell into the market, and 4,306,977 shares of common stock are

issuable upon exercise of awards granted under our 2017 Stock Incentive Plan and 2012 Equity Incentive Plan.

Under our Amended and Restated

Loan and Security Agreement, Innovatus has the right, at its election and until August 9, 2025, to convert up to 20% of the outstanding

principal of the Term A Loan into shares of the Company’s common stock at a price per share of $10.00 (the “Conversion Right”).

Innovatus will continue to have the right to exercise a previously disclosed warrant granted to it under the Prior Loan Agreement to purchase

26,042 shares of common stock at a price per share of $14.40 through April 8, 2031.

In connection with the funding of each of the Term

C Loan, the Term D Loan, the Term E Loan and the Term F Loan, the Company agreed to issue to Innovatus and Oxford warrants to purchase

that number of shares of the Company’s common stock equal to 2.5% of the principal amount of the applicable Term Loan divided by

the exercise price, which shall, with respect to the Term C Loan, be equal to the lower of (i) the volume weighted average closing price

of the Company’s common stock for the five-trading day period ending on the last trading day immediately preceding the execution

of the A&R Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the A&R Loan

Accordingly, on May 30, 2024, the Company issued 103,876 warrants with an exercise price of $14.84 per share.

fair value of the warrants was approximately $1.2 million.

For the additional Term Loans, the exercise price will be based on the lower

of (i) the exercise price for the Warrants issued pursuant to the Term C Loan or (ii) the volume weighted average closing price of the

Company’s common stock for the five-trading day period ending on the last trading day immediately preceding the applicable Term

Loan funding.

The Warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary of the applicable funding

The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain

proportional adjustments as set forth in such Warrant.

Sales of substantial amounts of shares of our common

stock or other securities by these investors or our other stockholders or by us under the Open Market Sale Agreement SM , or

the perception in the market that the holders of a large number of shares of our common stock intend to sell their shares, could reduce

the trading price of our common stock, make it more difficult for you to sell your shares at a price that you desire and impair our ability

to raise capital through the sale of equity or equity-related securities.

Our Series A Preferred Stock has rights, preferences, and privileges

that are not held by, and are preferential to, the rights of holders of our common stock.

We issued 1,120,873 shares of Series A Preferred Stock

in a financing transaction in December 2022, and 317,577 shares of Series A Preferred Stock were outstanding as of December 31, 2024.

The Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock provides that, in the event

of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or in the event of a Deemed Liquidation Event (as

defined in the Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock), the holders

of Series A Preferred Stock are entitled to be paid from assets of the Company available for distribution to its stockholders, before

any payment is made to the holders of common stock by reason of their ownership thereof, an amount per share equal to the greater of (i)

the original issue price ($5.75 on an as-converted-to-common stock basis), plus all accrued and unpaid dividends and (ii) the amount that

the holder would have been entitled to receive at such time if the Series A Preferred Stock were converted into common stock.

may not, without the consent of holders of a majority of the outstanding shares of Series A Preferred Stock, amend its charter in a manner

that adversely affects the powers, preferences or rights of the Series A Preferred Stock or issue or obligate itself to issue shares of

any additional class or series of capital stock unless the same ranks junior to the Series A Preferred Stock with respect to the distribution

of assets on the liquidation, dissolution or winding up of the Company and the payment of dividends.

If securities or industry analysts do not publish research or reports

about our business, or publish negative reports about our business, our stock price and trading volume could decline.

The trading market for our common stock depends in

part on the research and reports that securities or industry analysts publish about us or our business.

We do not have any control over

these analysts.

There can be no assurance that analysts will cover us or provide favorable coverage.

If one or more of the analysts who

cover us downgrade our stock or change their opinion of our stock, our stock price would likely decline.

If one or more of these analysts

cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could

cause our stock price or trading volume to decline.

We incur increased costs as a result of operating as a public company,

and our management devotes substantial time to new compliance initiatives and corporate governance practices.

As a public company, we incur significant legal, accounting

and other expenses that we did not incur as a private company and that private company competitors do not incur.

The Sarbanes-Oxley Act,

the Dodd-Frank Wall Street Reform and Consumer Protection Act, the continued listing requirements of The Nasdaq Stock Market and other

applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of

effective disclosure and financial controls and corporate governance practices.

Our management and other personnel devote a substantial

amount of time to these compliance initiatives.

Moreover, these rules and regulations have increased our ongoing legal and financial compliance

costs and make some activities more time-consuming and costly.

Pursuant to Section 404 of the Sarbanes-Oxley Act,

or Section 404, we are required to furnish a report by our management on our internal control over financial reporting.

Depending upon

our filer status, we could also be required to include an attestation report on internal control over financial reporting issued by our

independent registered public accounting firm as required by Section 404(b).

While we, as of December 31, 2024, concluded that our internal

control over financial reporting was effective, we may need to dedicate additional internal resources and engage outside consultants to

maintain compliance with Section 404 in the future.

Any material weaknesses that we may identify in the future could result in an adverse

reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.

We do not currently intend to pay dividends on our common stock,

and, consequently, our stockholders’ ability to achieve a return on their investment will depend on appreciation in the price of

our common stock.

We currently intend to invest our future earnings,

if any, to fund our growth.

We do not currently intend to pay dividends on our common stock for the foreseeable future, and, consequently,

our stockholders’ ability to achieve a return on their investment will depend on appreciation in the price of our common stock.

There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.

or may issue in the future pursuant to equity or convertible debt financings, may be resold at any time in the discretion of the investors.

our A&R Loan Agreement, as amended by the First Amendment to the A&R Loan Agreement, the Second Amendment to A&R Loan Agreement

and the Third Amendment to the A&R Loan Agreement, Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (“Innovatus”),

has the right, at its election and until May 9, 2026, to convert up to 20% of the outstanding principal of the Term A Loan into shares

of the Company’s common stock at a price per share of $10.00.

In addition, Innovatus continues to have the right to exercise a

previously disclosed warrant to purchase 26,042 shares of common stock at an exercise price of $14.40 per share, and Innovatus and Oxford

Finance LLC, a Delaware limited liability company, and certain of its affiliates, continue to have the right to exercise previously disclosed

warrants to purchase 154,413 shares of common stock at an exercise price of $14.84 per share.

of substantial amounts of shares of our common stock or other securities by these investors or our other stockholders or by us under

the Open Market Sale Agreement SM , or the perception in the market that the holders of a large number of shares of our common

stock intend to sell their shares, could reduce the trading price of our common stock, make it more difficult for you to sell your shares

at a price that you desire and impair our ability to raise capital through the sale of equity or equity-related securities.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1A. Risk Factors